Back to GetFilings.com
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
[X] ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2003.
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____ to ____.
Commission file number 0-25852
THE MED-DESIGN CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 23-2771475
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2810 Bunsen Avenue, Ventura, CA 93003
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (805) 339-0375
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, Par Value $0.01 Per Share
(Title of Class)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No__
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K [ ].
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2). Yes _X_ No__
The aggregate market value of voting stock held by non-affiliates of the
registrant (computed by reference to the last reported sale price of such stock
on June 30, 2003) was $52,649,015. The number of shares of the registrant's
common stock outstanding as of February 25, 2004 was 16,622,690.
Documents incorporated by reference:
None
FORWARD-LOOKING STATEMENTS
This Report contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 that address, among other
things, acceptance of safety products by health care professionals; our
expectations regarding contract manufacturing of certain specialty devices; our
pursuit of additional collaborative arrangements; the ability to manufacture
certain specialty devices using our assembly system; plans to rely on our
strategic collaborators to pursue regulatory approvals; expectations regarding
the ability of our products to compete with the products of our competitors;
acceptance of our products by the marketplace as cost effective; the generation
of royalty revenues from our licensees; factors affecting the ability of Becton
Dickinson to sell products licensed from us; sufficiency of available resources
to fund operations; factors affecting the availability of capital; plans
regarding the raising of capital; the size of the market for our products; our
plans regarding sales and marketing; our strategic business initiatives; our
intentions regarding dividends and the launch dates of our licensed products.
These statements may be found under "Item 1-Business," "Item 1-Risk Factors" and
"Item 7-Management's Discussion and Analysis of Financial Condition and Results
of Operations" as well as in this Report generally. We generally identify
forward-looking statements in this Report using words like "believe,"
"anticipate," "will," "expect," "may," "could," "intend" or similar statements.
There are important factors that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements including
lack of demand or low demand for our products or for safety products generally;
a determination of Becton Dickinson to focus its marketing efforts on products
other than those licensed from us; delays in introduction of products licensed
by us due to manufacturing difficulties or other factors; our inability to
license or enter into joint venture or similar collaborative arrangements
regarding our other products; unanticipated expenses relating to our
manufacturing effort and other factors discussed in "Item 1 - Risk Factors" and
matters set forth in this Report generally. Readers are cautioned not to place
undue reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. We undertake no obligation to publicly
revise these forward-looking statements to reflect events or circumstances that
arise after the date hereof.
PART I
ITEM 1. BUSINESS
BUSINESS
We are principally engaged in the design, development and licensing of
safety medical devices intended to reduce the incidence of accidental needle
sticks. Each safety medical device we design and develop incorporates our
proprietary needle retraction technology. Our technology enables health care
professionals to retract a needle into the body of the medical device for safe
disposal without any substantial change in operating technique. Our product
technology generally can be categorized into the following five groups:
o hypodermic syringes used to inject drugs and other fluids into the
body;
o injectors used to inject drugs and other fluids into the body from a
pre-filled cartridge, vial or carpule;
o fluid collection devices used to draw blood or other fluids from the
body;
o venous and arterial access devices used to provide access to
patients' veins and arteries; and
o specialty safety devices for needle based and other applications.
We design our product technology to be similar to standard non-safety
medical devices in appearance, size, performance and operation. We believe that
this similarity is important, because health care professionals are more likely
to accept safety products that do not require a change in operating technique
from products they have traditionally used.
1
We have licensed a number of applications of our product technology to
medical device manufacturers, principally Becton Dickinson and Company ("BD").
In two instances, however, we arranged for the manufacture of products
incorporating our product technology through collaborative arrangements with
manufacturers. One of these products, the 1Shot Safety Dental Syringe, was
launched in June, 2003. We will continue to explore additional opportunities to
manufacture selected products in this manner.
Med-Design Strategy
Our goal is to become the leading developer of safety medical devices
designed to reduce the incidence of accidental needlesticks. The principal
elements of our strategy are to:
o license some of our currently unlicensed products to established
medical device manufacturers;
o modify and improve our current product technology in response to
market research and input provided by medical professionals;
o develop additional safety medical devices incorporating our core
technology in response to the specific requests and needs of our
current and potential licensees and potential strategic
collaborators;
o enter into collaborative arrangements with major pharmaceutical and
medical device companies where such arrangements would provide for
greater revenue opportunities than licensing; and
o pursue opportunities to manufacture or have manufactured selected
products pursuant to collaborative arrangements in which our
collaborators will be responsible for marketing and distribution.
Med-Design Products
We have designed and developed a number of products incorporating our
needle retraction technology. Our products are similar in appearance, size and
performance to standard non-safety products and are operated in essentially the
same manner. A brief description of each of our products follows:
Licensed Products
Products Licensed to Becton Dickinson
BD, a major medical technology company, is the principal licensee of
our patented product technology. Pursuant to two licensing agreements, we have
granted BD the exclusive worldwide rights to manufacture and market our patented
product technology in three fields of use, injection syringe, IV catheters and
blood collection. The agreements with BD provide for continuing royalty payments
based upon BD's net sales of the licensed product technology, subject to annual
minimums.
The following product technologies are currently under license to BD:
o Safety Syringe (fixed needle). After the medication in the
syringe has been delivered, the user applies a light amount of
additional pressure in order to move the plunger slightly beyond
the normal stop point, which causes the needle to automatically
and fully retract into the body of the syringe. The fixed needle
Safety Syringe can be manufactured with needles of various gauges
and sizes, and barrels with various sizes. BD currently markets
the BD Integra(TM) 3ml Syringe, which incorporates our Safety
Syringe technology and was introduced in 2002.
o Safety Syringe (luer needle). The luer needle Safety Syringe is a
hypodermic needle with a mating needle/hub assembly.
o Safety Tuberculin/Insulin Syringe. The Safety Tuberculin/Insulin
Syringe is a smaller version (1ml) of the fixed needle Safety
Syringe. BD currently markets the BD Integra(TM) 1ml Syringe,
which incorporates our Safety Tuberculin/Insulin Syringe
technology and was introduced in the United States in February
2004.
2
o Safety Blood Collection Needle. The Safety Blood Collection
Needle is compatible with substantially all standard blood
collection needle accessories. After sufficient fluids have been
extracted from the body, by depressing a conveniently located
button on the barrel of the device, the needle automatically and
fully retracts into the body of the device. The needle seals in
place rendering it harmless and inoperable. BD currently markets
the BD Vacutainer(TM) Push Button Collection Set, which
incorporates our Safety Blood Collection Needle technology and
was introduced in December 2003.
o Safety Winged Blood Collection Set. The Safety Winged Blood
Collection Set uses a smaller diameter needle than the Safety
Blood Collection Needle and is an alternative to that device. It
is compatible with substantially all standard blood collection
needle accessories.
o Safety IV Catheter. Catheters are inserted into veins or other
areas of the body using a catheter insertion needle located
within the flexible catheter tube. After the insertion needle is
partially removed from the Safety IV Catheter, the needle
automatically and fully retracts into the body of the catheter
insertion device. The needle seals in place rendering it harmless
and inoperable. BD currently markets the Autoguard Pro(TM)
Shielded IV Catheter, which incorporates our Safety IV Catheter
technology and was introduced in 2002.
o Safety PICC Introducer. The Safety PICC Introducer is a catheter
insertion device used to insert a peripherally inserted control
catheter (PICC) for long term venous access to deliver fluids
into a patient.
o Safety Wing Needle Set/Catheter. The Safety Wing Needle
Set/Catheter is used to continuously deliver fluids into a
patient's vein. The sharp end of the needle is completely
shielded within the device, allowing intravenous fluid from a
gravity bag or infusion pump to flow through the retracted steel
needle. Upon completion of the infusion therapy, the Safety Wing
Needle Set/Catheter may be removed from the patient with no
possibility of an accidental needle stick.
The licensing agreement with BD for the Integra(TM) Syringe provided
for a two-tier royalty payment. A dispute arose in July 2002 between us and BD
as to the appropriate amount of royalty payment for the BD Integra Syringe. We
submitted the dispute to mediation and reached an agreement in January 2003 that
resolved the dispute and provided that BD will pay us a royalty rate of 2.5% on
all sales of the product in the U.S. and in all International markets where our
retracting needle syringe patents are in force. The royalty rate is retroactive
to the initial introduction date of May 2002 for the BD Integra 3ml Syringe and
is also applicable to the BD Integra 1ml Syringe.
Enpath Medical Inc. (formerly Medamicus, Inc.)
We licensed to Enpath Medical Inc. the Safety Seldinger Device
initially for venous access and subsequently for arterial access. We receive
royalties from the sale of the device by Enpath Medical Inc. The Safety
Seldinger Device agreement involves a lower volume, higher margin product
directed to a specialized niche market segment.
Manufactured Products Under Agreement
In connection with our efforts to enter into collaborative arrangements
for the marketing and distribution of certain of our product technologies, we
determined that we could enhance our efforts with potential strategic
collaborators that do not possess manufacturing capabilities if we could arrange
to have the products manufactured. We entered into two OEM Manufacturing
Agreements with Owens-Illinois Closure, Inc. for the manufacture of our Safety
Pre-filled Cartridge Injector and Safety Dental Cartridge Injector. Pursuant to
the terms of the agreements, we have purchased the automated equipment and molds
necessary for Owens-Illinois to manufacture the products. Owens-Illinois is
currently manufacturing the Safety Dental Cartridge Injector and Sultan Chemists
is marketing the product under the name 1Shot Safety Dental Syringe.
3
Safety Dental Cartridge Injector
The Safety Dental Cartridge Injector is used to administer anesthetics
in dental procedures and uses standard dental needles and anesthetic cartridges
capable of fluid removal. The Safety Dental Cartridge Injector allows for
multiple anesthetic injections, while rendering the needle safe between
injections.
We received FDA clearance for this device in February 2003 and launched
the 1Shot Safety Dental Syringe, a one-handed, single use, disposable safety
syringe, for sale in June 2003. The product is manufactured by Owens-Illinois in
accordance with the OEM Agreement and exclusively distributed worldwide by
Sultan Chemists. We began to recognize revenue on the sale of the product to
Sultan in 2003.
Safety Pre-filled Cartridge Injector.
The Safety Pre-filled Cartridge Injector enables medication to be
injected directly into a patient from pre-filled cartridges produced by many
pharmaceutical manufacturers. The Safety Pre-filled Cartridge Injector can be
manufactured with needles of various gauges and sizes. The cartridge snaps
directly onto the delivery system and becomes integrated as a functional part of
the plunger.
In June 2001, we entered into a co-promotion agreement with Abbott
Laboratories to co-market our pre-filled injector products to the pharmaceutical
industry in conjunction with Abbott's pharmaceutical fill/finish technology. As
of the end of 2003, Abbott and Med-Design were unsuccessful in identifying
partners for this technology. We are currently in discussions with several
pharmaceutical companies for the purchase of certain of our pre-filled devices,
but cannot be assured that any of these discussions will be successful.
Dual Chamber Pharmaceutical Mixing Device
The Dual Chamber Pharmaceutical Mixing Device is used to package, store
and mix pre-filled pharmaceutical compounds.
In February, 2004, we entered into a development agreement with Atrix
Laboratories to develop a dual chamber pharmaceutical mixing device for the
packaging of certain pre-filled liquid pharmaceutical products. The development
and evaluation phase is expected to last several months. Under the agreement, if
the development phase is successful, we and Atrix will use best efforts to
pursue a long-term contract under which we would license the technology to Atrix
and manufacture and supply the dual chamber device to Atrix.
Portfolio Products
We are seeking to license technology or enter into collaborative
arrangements for a number of additional applications of our technologies
described below. All of the products derived from these applications would
incorporate our needle retraction technology.
Safety Pre-filled Dual Chamber Injector. The Safety Pre-filled Dual
Chamber Injector allows medication to be injected directly into a patient from
freeze-dried powders produced by many pharmaceutical manufacturers. In the first
step, sterile water, in one chamber, is introduced into the freeze-dried powder
chamber. This introduction quickly mixes the water and powder, allowing for the
injection. The Safety Pre-filled Dual Chamber Injector can be manufactured with
needles of various gauges and sizes.
Safety Pre-filled Vial Injector. The Safety Pre-filled Vial Injector
allows medication to be injected directly into a patient from pre-filled vials
produced by many pharmaceutical manufacturers. The pre-filled vial is threaded
onto the rear end of the stationary plunger and becomes integrated as a
functional part of the plunger. The Safety Pre-filled Vial Injector can be
manufactured with needles of various gauges and sizes.
Safety Arterial Blood Gas Needle. Arterial blood gas needles are used
to collect small samples of arterial blood and deliver the blood to a blood gas
analyzer, after which the filled needle barrel is ready for delivery to a
laboratory for analysis. The Safety Arterial Blood Gas Needle is designed for
conventional laboratory processing and attaches to any standard blood gas needle
with a luer fitting, as would a non-safety needle.
4
Safety Blood Donor Needle Set. The Safety Blood Donor Needle Set is
used to collect large volumes of blood for blood bank storage. The Safety Blood
Donor Needle Set is compatible with all standard blood bag tubing sets and can
be manufactured to include a safety blood sampling adapter.
Safety Winged A-V Fistula Needle. Safety Winged A-V Fistula Needles are
used to access veins and arteries to perform a hemodialysis procedure.
Hemodialysis removes toxic wastes from the blood of patients in renal failure.
Safety Spinal/Epidural Needle. The Safety Spinal/Epidural Needle can be
used for a variety of anesthesia and spinal procedures requiring both fluid
removal and fluid injection. The Safety Spinal/Epidural Needle is compatible
with all standard gauge size needles and allows for fluid removal or injection
with a luer syringe.
Safety Y-Port Infusion Needle. Y-Ports are devices used in intravenous
therapy that allow the delivery of secondary fluids into a primary intravenous
fluid line.
We completed a private equity placement of 3,598,844 shares of our
common stock and warrants to purchase 1,199,607 shares of our common stock on
August 1, 2003, in which we received net proceeds of approximately $16,000,000.
We intend to use the proceeds to enhance our manufacturing capabilities by
either funding an acquisition of a medical device manufacturing company or by
entering into additional manufacturing agreements for the portfolio products. In
this regard, if we are successful in developing a dual chamber pharmaceutical
mixing device for the packaging of certain pre-filled liquid pharmaceutical
products under our development agreement with Atrix, we expect to enter into an
agreement with a third party manufacturer for the production of the device.
Sales and Marketing
Our marketing efforts focus upon identifying, principally through the
use of publicly available information, market leaders in the pharmaceutical and
medical device industries who we believe have either a desire to incorporate
safety applications in their existing products or who have the ability to
distribute our products. We seek collaborative arrangements with these companies
under which we would manufacture or arrange to have manufactured our products or
through which our needle retraction technology is applied to their existing
products.
In addition to direct marketing efforts, safety needle legislation and
our relationship with BD have increased industry awareness of our products.
While several potential licensees and strategic collaborators have contacted us
to discuss the possibility of applying our needle retraction technology to their
existing products, we cannot predict whether these contacts will result in
definitive agreements.
Research and Development
Our research and development efforts in the past have focused primarily
upon the design and development of our needle retraction technology and the
design and development of specific applications of our technology for
incorporation into the products described above as well as, in certain
instances, the equipment necessary to assemble the products. Research and
development expenses were $1,484,891, $1,969,709 and $1,073,323 in 2003, 2002
and 2001, respectively. Our research and development efforts going forward will
focus primarily upon:
o the modification and improvement of our current product technology in
response to market research and input from health care professionals;
and
o the development of new safety medical devices in response to the
specific requests and needs of our licensees and potential strategic
collaborators.
Our research and development staff consisted of eight employees as of
December 31, 2003.
5
Facilities and Manufacturing
Our primary focus has been on the design, development and licensing of
safety medical devices. To date, in most cases our licensees have arranged for
manufacturing of products incorporating the technology licensed from us. In
2001, to enhance our efforts with potential partners that do not possess
manufacturing capabilities, we entered into two OEM Manufacturing Agreements
with Owens-Illinois for the manufacture of our Safety Pre-filled Cartridge
Injector and Safety Dental Cartridge Injector. Under the terms of the
agreements, we purchased the equipment and molds necessary for Owens-Illinois to
manufacture the Safety Dental Cartridge Injector.
We will continue to explore additional opportunities to manufacture
selected products pursuant to collaborative arrangements in which our strategic
collaborators will be responsible for marketing and distribution. We expect that
these products would involve production levels that are substantially lower than
the products of the type licensed to BD.
In July 2003, we were recommended for certification to ISO 13485:1996
by KEMA Registered Quality, Inc., our notified body. This is a recognized
quality standard for medical device manufacturers that will enable us to apply
for international registrations for products we intend to sell internationally.
We lease an approximately 26,000 square foot facility in Ventura,
California. In addition to our corporate offices, the facility includes space
for the following:
o a research and development laboratory equipped with assembly and test
equipment for concept modeling and product development;
o a machine shop equipped with tools for the fabrication of new product
parts for concept modeling and assembly; and
o a 3,120 square foot class 100,000 clean room used for the assembly of
prototypes.
Nevertheless, as noted above, our strategy is to utilize a contract
manufacturer to manufacture products for commercial distribution.
Government Regulation
Our products are subject to regulation by the United States Food and
Drug Administration (FDA) under a number of statutes including the Federal Food,
Drug and Cosmetic Act (FDCA). The FDA regulates, among other things, the
research, development, testing, manufacture, labeling, distribution, and
promotion of medical devices in the United States. Our medical devices must be
cleared or approved by the FDA before they can be sold in the United States.
Historically, our focus has been on the development, design and
licensing of medical safety devices rather than marketing and manufacturing of
the devices. Therefore, we had not typically made the regulatory filings
necessary to sell our products. Rather, we have relied on our licensees and
other strategic collaborators to pursue regulatory approvals. We anticipate that
we will continue to rely on our strategic collaborators to seek regulatory
compliance if we license our products to them.
We have decided to commercially market, through our strategic
collaborators, and have manufactured, through contract manufacturers, some of
the products we develop separate from our current or any future license
agreements in 2002. We will be required to file for marketing authorization for
these products. The FDCA provides two basic review procedures by which medical
devices can receive FDA marketing authorization. Certain products qualify for a
submission authorized by Section 510(k) of the FDCA. To receive Section 510(k)
clearance, a pre-market notification must be filed with the FDA that a company
plans to begin marketing a medical device. The filing must establish that the
medical device is substantially equivalent to another medical device that has
been granted prior FDA pre-market notification clearance or was marketed prior
to May 28, 1976, the date of enactment of the Medical Device Amendments.
Marketing may commence when the FDA issues a letter finding substantial
equivalence. If a product does not qualify for Section 510(k) clearance, a
pre-market approval application must be filed. Pre-market approval applications
(PMAs) must demonstrate that the medical device is safe and effective. The
pre-market approval process is typically more complex and time consuming than
the Section 510(k) clearance process, and generally requires the submission of
laboratory, pre-clinical and clinical data. Before initiating clinical trials,
companies sponsoring such trials often must seek and obtain an Investigational
Device Exemption.
6
Since we will commercially market and have manufactured some of the
products we develop, separate from our current or any future license agreement,
we may be required to file for Section 510(k) clearance, or possibly pre-market
approval, for such products. In that case, we would be subject to device user
fees. The Medical Device User Fee and Modernization Act, enacted in 2002,
authorizes the FDA to assess and collect user fees for Section 510(k) premarket
notifications and premarket approval applications filed on or after October 1,
2002. Fees for fiscal year 2004 range from $3,480 for Section 510(k) premarket
notifications to $206,811 for PMAs, although fee reductions are available for
companies qualifying as small businesses. If we commercially manufacture and
market devices, we also would be required to comply with FDA post-market
reporting requirements, including the submission of reports on certain adverse
events and malfunctions, and requirements governing the promotion of medical
devices. In addition, modifications to our devices may require the filing of new
510(k) submissions or pre-market approval supplements, and we will need to
comply with FDA regulations governing medical device manufacturing practices.
The FDA and the California Department of Health Services (DHS) require medical
device manufacturers to register as such and subject them to periodic FDA and
DHS inspections of their manufacturing facilities. The FDA requires that medical
device manufacturers produce devices in accordance with the FDA's current
Quality System Regulation (QSR), which governs the methods, facilities and
controls used for the design, manufacture, testing, packaging, labeling and
storage of medical devices. We are not currently required to register our pilot
manufacturing facility or comply with QSR requirements because we do not
commercially manufacture and distribute the devices we produce in our facility,
but we will be required to register and comply if we commence commercial
manufacturing. To ensure compliance with QSR requirements, we would need to
expend time, money and effort in the area of production and quality control.
There is a different set of regulatory requirements in place for the
European Union (EU). In the EU the company putting a medical device onto the
market must comply with the requirements of the Medical Devices Directive (MDD)
and affix the CE mark to the product to attest to such compliance. To achieve
this, the medical devices in question must meet the "essential requirements"
defined under the MDD relating to safety and performance, and the relevant
company must successfully undergo a verification of its regulatory compliance by
a third party standards certification provider, referred to in the legislation
as a "Notified Body." The nature of the assessment will depend on the regulatory
class of products concerned, which in turn determines the precise form of
testing to be undertaken by the Notified Body.
The requirements of the MDD must be complied with by the "manufacturer
of the device," which is defined as the party responsible for the design,
manufacture, packaging and labeling of the device before it is placed on the EU
market, regardless of whether these operations are carried out by this party or
on its behalf.
Accordingly, where medical devices are marketed by our licensees or
strategic collaborators under their names, compliance with the MDD will be their
responsibility. In the event that we decide to manufacture devices to be
distributed in the EU market under our name, all compliance responsibilities
will be borne by us.
In the case of devices such as certain versions of the safety
pre-filled vial injector, which incorporates a medicinal product as one
integrated product, the regulatory requirements are those relating to medicines
as opposed to devices and an application for a marketing authorization must be
made under Directive 65/65 EEC. However, the safety and performance of the
device features of the integral product are assessed in accordance with the
essential requirements of Annex I of the MDD. Again, if the device is marketed
by our licensees or strategic collaborators under their names, all regulatory
compliance obligations will be borne by such licensees or strategic
collaborators. The party responsible for regulatory compliance will be subject
to continued surveillance by the Notified Body and will be required to comply
with additional national requirements that are beyond the scope of the MDD.
7
Competition
The safety medical device market is highly competitive. Licensees of
our products and our other strategic collaborators compete in the United States
and abroad with the safety products and standard products manufactured and
distributed by companies such as:
o Tyco International, Inc. (Kendall Healthcare Products Company),
o B. Braun,
o Terumo Medical Corporation of Japan,
o Medi-Hut, Inc., and
o Johnson & Johnson.
Developers of safety medical devices which we compete against for
license and collaborative arrangements with medical device and pharmaceutical
companies include:
o New Medical Technologies,
o Retractable Technologies, Inc.,
o Univec, Inc.,
o Specialized Health Products International, and
o Safety Syringes, Inc.
Traditionally, competition regarding non-safety medical devices was
primarily based upon price with little differentiation between products. We
expect that products incorporating our technology will compete against both
safety products and non-safety products based upon safety and ease of use and
disposal. While safety medical devices are priced at approximately two to three
times that of equivalent standard medical devices, we believe that based upon
estimated costs associated with accidental needlesticks, products incorporating
our technology should be considered cost effective by the marketplace. There can
be no assurance, however, that purchasers will be willing to pay the increased
price for safety medical devices unless they are mandated to use such devices by
laws such as those passed by the federal government and those passed at the
state level in California, Tennessee, Texas, New Jersey and Maryland.
Legislation
Regulatory actions at the federal and state level promote the use of
safety needles to reduce the risk of accidental needlesticks. On July 1, 1999,
California, through its state Occupational Safety and Health Administration
(OSHA) program, began requiring the use of safety needles. Other states such as
Texas, Tennessee, Maryland and New Jersey have passed similar legislation.
On November 6, 2000, President Clinton signed the Needlestick Safety
and Prevention Act amending OSHA's Bloodborne Pathogens Standard to require that
employers implement the use of safer medical devices in their facilities. To
implement the statutory mandates in the Needlestick Safety and Prevention Act,
OSHA issued a number of further revisions to its Bloodborne Pathogens Standard.
The revised standard became effective on April 18, 2001, and imposes several
needle device safety requirements on employers, including:
o evaluation and implementation of safer needle devices as part of the
re-evaluation of appropriate engineering controls during an
employer's annual review of its exposure control plan;
o documentation of the involvement of non-managerial, frontline
employees in choosing safer needle devices; and
o establishment and maintenance of a sharps injury log for recording
injuries from contaminated sharps.
8
On November 27, 2001, OSHA issued a compliance directive (CPL 2-2.69)
that advises OSHA's regional offices on the proper interpretation and
enforcement of the revised Bloodborne Pathogens Standard provisions. The
compliance directive confirms that the consideration of safer needle devices in
annually reviewing and updating the exposure control plan is a critical element
of the Bloodborne Pathogens Standard. The compliance directive also stresses
that the standard requires employers to use engineering controls (e.g., safer
needle devices) if such controls will remove or eliminate the hazards to
employees. As a result of these regulatory actions, the demand for safety
medical devices has increased, and we believe that this demand will continue to
increase.
Patents and Proprietary Rights
Our success will depend in part on our ability to obtain and maintain
patent protection for our products, to preserve our trade secrets and to operate
without infringing the proprietary rights of third parties. It is our policy to
protect our intellectual property and maintain the proprietary nature of our
technology by filing patent applications for technology we consider important to
the development of our business and by requiring employees and key consultants
to execute non-disclosure and non-compete agreements.
We have 24 United States patents with expiration dates ranging from
April 29, 2007 to April 30, 2021 covering our retractable needle technology and
specific product applications based upon our technology. In addition, we have 20
foreign national patents and 5 European patents covering at least 10 countries,
with expiration dates ranging from November 7, 2010 to August 28, 2019. We also
have 22 United States, 115 foreign national, 22 European and 2 international
patent applications pending. We also have a United States design patent based on
one of our products, in addition to 6 foreign national design registrations.
Employees
As of December 31, 2003, we had 18 full-time employees and 2 part-time
employees, most of whom were located at our corporate offices.
We maintain a website at www.med-design.com and make available free of
charge through this website our annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K and amendments to those reports filed
or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as
reasonably practicable after the company electronically files such material
with, or furnishes it to, the SEC. The material on our website is not part of
this report, and the reference to our website address is intended to be an
inactive textual reference only.
RISK FACTORS
We have a history of net losses and anticipate we will incur continued losses
for the foreseeable future.
We have incurred significant losses since inception. As of December 31,
2003, our accumulated deficit was $43,279,731. Among other things, our ability
to achieve profitability is dependent upon:
o the successful marketing of products incorporating our technology by
licensees;
o our ability to license additional product technologies that are not
currently subject to licenses or have products incorporating our
technology distributed through joint venture or similar arrangements;
and
o our ability to develop additional products incorporating our core
technology.
We have licensed to BD several of our product technologies. Four
products subject to the license have been launched to date, the latest of which
is the BD Vacutainer(TM) Push Button Collection Set, launched in 2003 and the 1
ml version of the Integra Syringe in February 2004. We are unable to predict
whether BD's marketing efforts will be successful and whether the licenses will
generate meaningful revenues for us. If our licensees are not successful in
marketing products incorporating our technology, and if we are not successful in
licensing or entering into other suitable arrangements relating to the sale of
additional products incorporating our technology, we may never generate
meaningful revenues, in which case our long-term viability would be threatened.
9
We are dependent upon our licensing agreements with BD, and if BD is not
successful in selling, or determines not to pursue the sale of, products
incorporating technology licensed from us, our business will be harmed.
To date, substantially all of our revenues have been derived from "up
front" license payments made by BD and Enpath Medical Inc. (formerly Medamicus)
under license agreements with us. We anticipate that royalty payments from BD
related to sales of products incorporating our technology will represent a
substantial portion of our revenues for at least the next twelve months. BD has
the right to terminate its license agreement with us upon 60 days' notice and
would be subject to no further funding obligations to us with respect to the
products incorporating our technology licensed under the agreement. The ability
of BD to sell products subject to the license agreement will depend on
competitive factors and the resources BD commits to the sale of the products.
The extent to which BD commits its resources to the sale of products is entirely
within BD's control. BD is not obligated to pursue the development and
commercialization of these products. Therefore, our licensing arrangements with
BD may not result in the successful commercialization of products incorporating
our technology and may not generate any future royalty payments. If BD
terminates the licensing agreements, is unsuccessful in developing or selling
the products subject to the license agreement or otherwise determines not to
pursue the development and sale of these licensed products, our business will be
significantly harmed.
If we engage in any acquisition or business combination, we will incur a variety
of risks that could adversely affect our business operations.
From time to time we have considered, and we will continue to consider
in the future, strategic business initiatives intended to further the
development of our business. These initiatives may include acquiring businesses,
technologies or products or entering into a business combination with another
company. If we pursue such a strategy, we could, among other things:
o issue equity securities that would dilute our stockholders'
percentage ownership;
o utilize substantial cash resources and incur substantial debt, which
may place constraints on our operations;
o spend substantial operational, financial and management resources in
integrating new businesses, technologies and products;
o assume substantial actual or contingent liabilities; or
o merge, or otherwise enter into a business combination with, another
company, in which our stockholders would receive cash or shares of
the other company, or a combination of both, on terms that our
stockholders might not deem desirable.
Moreover, any strategic business initiative may not provide anticipated
benefits and could, if unsuccessful, hurt our long-term business prospects.
If we are unable to raise additional funds as required, we may have to reduce
the scope of, or cease, our operations.
We believe that we have sufficient funds to support our planned
operations and capital expenditures for at least the next twelve months. The
availability of resources over a longer term will be dependent on our ability to
enter into licensing agreements and to receive royalty payments from our current
and future licensees and our ability to enter into, and profitably operate under
joint venture or similar arrangements. If we are unsuccessful in negotiating
additional agreements, or if licensing revenues are insufficient to support
operations, we may seek to raise funds through public or private equity
offerings or debt financings.
10
If we raise additional capital by issuing equity securities, our
stockholders' percentage ownership will be reduced, and our stockholders may
experience substantial dilution. In this regard, we issued 3,598,844 shares of
our common stock in a private placement completed in August 2003, from which we
received net proceeds of approximately $16,000,000. Any equity securities issued
in future equity offerings may provide rights, privileges or preferences
superior to our common stock. If we raise additional funds by issuing debt
securities, we may be subject to significant restrictions on our operations. If
we raise additional funds through joint ventures or other collaborations and
license arrangements, we may be required to relinquish rights to our technology
or products incorporating our technology or grant licenses on terms that are not
favorable to us.
If adequate funds are not available on acceptable terms, we may have to
reduce the scope of, or cease, our operations.
Products incorporating our technology must receive regulatory approval in the
United States and foreign jurisdictions; we rely on our licensees to obtain such
approvals when we license our product technology, and if they are not successful
in obtaining or maintaining approvals, the sale of products incorporating our
technology and our ability to realize royalty revenues would be impaired.
Products incorporating our technology are medical devices subject to
regulation by the United States Food and Drug Administration (FDA). The FDA
regulates, among other things, product manufacture, labeling, distribution, and
promotion of medical devices in the United States. Medical devices incorporating
our technology must be cleared or approved by the FDA before they can be sold in
the United States.
Our licensees pursue regulatory approvals. As a result, our ability to
receive royalties from products incorporating our licensed technology may be
impaired or delayed if the licensees do not devote sufficient resources to the
regulatory approval effort. Moreover, obtaining FDA approval or clearance to
market a product can be a lengthy and costly process, which in some cases
involves extensive clinical studies. Our licensees may not be able to obtain the
necessary FDA authorizations to enable marketing of products incorporating
licensed technology in a timely fashion, or at all.
Even if our licensees obtain the necessary approvals or clearances,
later problems with the product could cause the FDA to suspend or revoke the
approvals or clearances. Also, if the FDA authorizes marketing of products
incorporating licensed technology, our licensees will be subject to continuing
requirements governing, among other things, modifications made to the products'
labeling, the claims that can be made for the products, reporting of adverse
events and recalls and manufacturing processes. We could confront similar
difficulties and obstacles if, in connection with joint venture or similar
arrangements, we directly pursued regulatory approvals or clearances. Failure to
comply with the FDA's requirements can result in issuance of FDA Warning
Letters, agency refusal to approve or clear products, revocation or withdrawal
of approvals previously granted, product seizures, injunctions, recalls,
operating restrictions, limitations on continued marketing and civil and
criminal penalties.
There is a different set of regulatory requirements in place for the
European Union (EU). To market a product in the EU a manufacturer must be
entitled to affix to the device a CE marking, which is a European symbol of
adherence to quality assurance standards and compliance with applicable European
medical device directives. A CE marking allows a device to be marketed in all
member states of the EU and accordingly, failure to be entitled to affix a CE
marking will prohibit the marketing of a device anywhere in the EU.
The responsibilities for compliance with the CE requirements lies with
the "manufacturer of the device," which is defined in the Medical Devices
Directive (MDD) as the party responsible for the design, manufacture, packaging
and labeling of the device before it is placed on the EU market, regardless of
whether these operations are carried out by this party or on its behalf.
Accordingly, we rely upon our licensees and strategic collaborators under whose
names products incorporating our technology are marketed to satisfy the
necessary compliance criteria, and if our licensees do not devote sufficient
resources to this process, our ability to receive royalties from the sale of the
products by the licensees and strategic collaborators will be diminished.
Furthermore, the licensees and strategic collaborators may not be able to
satisfy the necessary requirements to allow marketing of products based on our
technology in a timely fashion or at all.
In the case of devices incorporating a medicinal product as a single
integrated product, such as the safety pre-filled glass syringe, the regulatory
requirements are those relating to medicines as opposed to devices, in which
case our licensees and, if applicable, our strategic collaborators, must make an
application for a marketing authorization under Directive 65/65 EEC. The
application must be made to one EU country, and if approved, is then mutually
recognized in all other remaining EU countries. The process can be very lengthy,
if authorization is granted at all.
Our failure or the failure of our licensees or strategic collaborators
to comply with the FDA and other applicable foreign or domestic regulations
could cause our business to be harmed significantly.
11
Products manufactured under our control through a contract manufacturer must
receive regulatory approval and if we are not successful in obtaining or
maintaining approvals, the sale of these products would be suspended.
We plan to manufacture and market some products incorporating our
technology, either ourselves, or through joint ventures or other contractual
arrangements under which third parties manufacture and, in some instances, sell
our products. These contractual arrangements will require us to seek separate
clearance or approval by the FDA of these products, to pay user fees for
applications filed and to comply with ongoing FDA requirements for submission of
safety and other post-market information. These arrangements also may involve
our assumption of commercial manufacturing responsibility with respect to some
of our products. If we engage in commercial manufacturing, we will be required
to adhere to requirements pertaining to the FDA's current Quality System
Regulation, commonly known as the QSR. The current QSR requirements govern the
methods, facilities and controls used for the manufacture, testing, design,
packaging, labeling and storage of medical devices. Compliance with QSR
requirements will involve continued expenditure of time, money, and effort. We
may not be able to comply with current QSR regulations or other FDA regulatory
requirements, resulting in delay or inability to manufacture the products. To
the extent that we utilize contract manufacturers, those manufacturers will be
subject to the QSR and other requirements described above.
Our failure or the failure of our licensees or contract manufacturers
to comply with FDA and other applicable regulations could cause our business to
be harmed significantly.
We are dependent on our licensees and contract manufacturers for the manufacture
of products incorporating our technology.
We previously have relied on our licensees to arrange for the
commercial manufacture of products incorporating our technology. Our licensees
generally manufacture products incorporating our technology at their own
facilities. Pursuant to an agreement between Owens-Illinois, Closure Inc. and
us, Owens-Illinois is manufacturing one of our products and may manufacture
another if we enter into a distribution agreement for that product. Contracting
with third parties or relying on licensees to manufacture products incorporating
our technology presents the following risks:
o delays in the manufacture of the products could have a material
adverse effect on the marketing of the products;
o the manufacturers may not comply with requirements imposed by the FDA
or other governmental agencies, which are described in the preceding
risk factor;
o we may have to share intellectual property rights to improvements in
the manufacturing processes or new manufacturing processes for the
products;
o in those instances where we seek third party manufacturers, we may
not be able to locate acceptable manufacturers or enter into
favorable long-term agreements with them; and
o we may not be able to find substitute manufacturers, if necessary.
Any of these factors could delay commercialization of products
incorporating our technology and adversely affect the sale of the products and
our license or joint venture revenues.
If we are unable to protect our proprietary technology, or to avoid infringing
the rights of others, our ability to compete effectively will be impaired.
Our intellectual property consists of patents, licenses, trade secrets
and trademarks. Our success depends in part on our ability to:
o obtain and maintain patents and other intellectual property;
12
o establish and maintain trademarks;
o operate without infringing the proprietary rights of others; and
o otherwise maintain adequate protection of our technology and products
in the United States and other countries.
We have a number of patents and pending United States patent
applications relating to our product technology. Patent applications filed by us
or on our behalf may not result in patents being issued to us. Even if a patent
is issued, the patent may not afford protection against competitors with similar
technology. Furthermore, others may independently develop similar technology or
duplicate our technology.
Our commercial success depends in part on our avoiding the infringement
of patents and proprietary rights of other parties and developing and
maintaining a proprietary position with regard to our own technology and
products. We cannot predict with certainty whether we will be able to enforce
our patents. We may lose part or all of our patents as a result of challenges by
competitors. Patents that may be issued, publications relating to technology
subject to our patent applications or other actions could block our ability to
obtain patents or to operate as we would like. Others may develop similar
technology or duplicate technology that we have developed or claim that we are
infringing their patents.
We may become involved in litigation or interference proceedings
declared by the U.S. Patent and Trademark Office, or oppositions or other
intellectual property proceedings outside of the United States. If any of our
competitors have filed patent applications or obtained patents that claim
inventions that we also claim, we may have to participate in an interference
proceeding to determine who has the right to a patent for these inventions in
the United States. If a litigation or interference proceeding is initiated, we
may have to spend significant amounts of time and money to defend our
intellectual property rights or to defend against infringement claims of others.
Litigation or interference proceedings could divert our management's time and
effort. Even unsuccessful claims against us could result in significant legal
fees and other expenses, diversion of management time and disruption in our
business. Any of these events could harm our ability to compete and adversely
affect our business.
An adverse ruling arising out of any intellectual property dispute
could invalidate or diminish our intellectual property position. An adverse
ruling could also subject us to significant liability for damages, prevent us
from using processes or products, or require us to license intellectual property
from third parties. Costs associated with licensing arrangements entered into to
resolve litigation or an interference proceeding may be substantial and could
include ongoing royalties. We may not be able to obtain any necessary licenses
on satisfactory terms.
In addition, we rely on trade secrets to protect technology. We attempt
to protect our proprietary technology by requiring certain of our employees and
key consultants to execute non-disclosure and non-competition agreements.
However, these agreements could be breached, and our remedies for breach may be
inadequate. In addition, our trade secrets may otherwise become known or
independently discovered by our competitors. If we lose any of our trade
secrets, our business and ability to compete could be harmed.
Because we are dependent on a single core technology, we are particularly
vulnerable to the development of products incorporating competing technology and
technological change.
All of the products we have designed and developed to date, and
products we currently intend to design and develop, are based upon our
proprietary retraction technology. Our focus on a single core technology makes
us vulnerable to the development of superior competing products and changes in
technology that could eliminate any demand for products incorporating our
technology. Our business would suffer if a superior competing product were
developed, or if there were a reduced demand for products incorporating our
technology. Moreover, we may not be able to successfully develop additional
product applications of our technology.
13
We are dependent on key personnel, and if we are unable to retain these
personnel, our business could be harmed.
Our success depends upon the skills, experience and efforts of our
executive officers and certain marketing and technical personnel. We are
particularly dependent upon the services of James M. Donegan, our Chief
Executive Officer. If Mr. Donegan, or any of our other key personnel, do not
continue in their present capacities, our operations could be materially
adversely affected.
Products incorporating our technology may not achieve market acceptance.
The use of safety needles is relatively new. Although the market for
syringes, fluid collection devices and infusion therapy devices is large, actual
sales of products incorporating our technology have not been significant. Sales
of products incorporating our technology will depend mostly upon our licensees'
ability to demonstrate the operational and safety advantages of products
incorporating our technology compared to standard syringes, fluid collection
devices and infusion therapy devices, and safety medical devices developed by
competitors. Our licensees and others who have contracted to sell products
incorporating our technology may be unable to sell products due to the higher
cost of safety medical devices relative to standard medical devices. There may
never be a significant demand for products incorporating our technology.
We are dependent on the sales and marketing efforts of our licensees and
strategic collaborators to sell products incorporating our technology, and our
business will suffer if our licensees or strategic collaborators do not
successfully market these products.
We currently have limited sales and marketing capabilities, and we do
not intend to build a sales and marketing infrastructure for commercial sales of
products incorporating our technology. Accordingly, we are dependent on our
licensees and other strategic collaborators to sell products incorporating our
technology and generate royalties for us. If our licensees and strategic
collaborators do not devote sufficient effort to the sale and marketing of
products incorporating our technology, or are otherwise unsuccessful in
marketing these products, our business will suffer. In this regard, the
co-promotion agreement with Abbott Laboratories to co-market our pre-filled
injector products has not been successful.
We are subject to product liability claims.
The manufacture and sale of medical devices entails an inherent risk of
liability in the event of product failure or claim of harm caused by product
operation. We may not be able to avoid product liability claims. Although we
currently maintain product liability insurance coverage ($1,000,000 per
occurrence and in the aggregate), such coverage may not be sufficient to protect
us or may not remain available at a reasonable cost. If we are unable to obtain
sufficient insurance coverage on reasonable terms or to otherwise protect
against potential product liability claims, we could be severely harmed if a
person brings a successful product liability claim against us.
Our markets are highly competitive.
The safety medical device market is highly competitive. Products
incorporating our technology will compete in the United States and abroad with
the safety products and standard products manufactured and distributed by
companies such as:
o Tyco International, Inc. (Kendall Healthcare Products Company),
o B. Braun,
o Terumo Medical Corporation of Japan,
o Med-Hut, Inc., and
o Johnson & Johnson.
14
Developers of safety medical devices against whom we compete include:
o New Medical Technologies,
o Retractable Technologies, Inc.,
o Univec, Inc.,
o Specialized Health Products International, Inc., and
o Safety Syringes, Inc.
Many of our competitors are substantially larger and better financed
than we are and have more experience in developing medical devices than we do.
These competitors may use their substantial resources to improve their current
products or to develop additional products that may compete more effectively
with products incorporating our technology. In addition, new competitors may
develop products that compete with products incorporating our technology, or new
technology may arise that could significantly affect the demand for products
incorporating our technology. We cannot predict the development of future
competitive products or companies. We will be materially adversely affected if
we are unable to compete successfully.
Our stock price is volatile.
Historically, our stock price, like the market price of the securities
of other companies engaged in the design and development of medical devices, has
fluctuated widely. In this regard, the closing price per share of our stock as
reported by Nasdaq declined from $42.15 on July 26, 2001 to $2.93 on April 9,
2003. On February 25, 2004, the closing price per share was $3.75. Our stock
price may be subject to similar future fluctuations in response to:
o announcements regarding technological innovations by us or our
competitors;
o the licensing of products or the formation of joint ventures or
similar arrangements by us or our competitors;
o government regulatory action regarding products incorporating our
technology;
o the development of new products by us or our competitors;
o general conditions in the medical device industry;
o quarter-to-quarter variations in operating results; and
o our failure to meet analysts' expectations.
Investors may lose money upon the resale of our shares.
Our common stock is subject to dilution.
As of December 31, 2003, there were 16,572,390 shares of our common
stock issued and outstanding. In addition, an aggregate of 3,686,125 additional
shares of our common stock are issuable pursuant to stock options granted under
our Non-Qualified Stock Option Plan and warrant agreements and 59,702 shares of
our common stock are subject to restricted stock grants. As of March 1, 2004,
144,073 shares of our common stock were available for issuance under our
Non-Qualified Stock Option Plan. Our common stock may be subject to further
dilution should we offer our equity securities in the future.
15
We are unlikely to pay dividends on our common stock.
No cash dividends have been paid on our common stock. We anticipate
that future earnings, if any, will be used to finance operations and expand our
business. Accordingly, we do not anticipate that we will pay cash dividends in
the future.
Provisions of our Certificate of Incorporation and the Delaware General
Corporation Law provide barriers to takeover offers even though such offers
could be beneficial to our stockholders.
Various provisions of our certificate of incorporation and bylaws and
Delaware law could delay or prevent a third party from acquiring shares of our
stock.
We have an authorized class of 5,000,000 shares of preferred stock,
none of which are issued and outstanding. The Board of Directors has the
authority, without shareholder approval, to issue preferred stock in one or more
series and to fix the relative rights and preferences of the preferred stock,
including their redemption, dividend and conversion rights. In addition, our
certificate of incorporation provides for a classified board of directors, with
each board member serving a staggered three-year term, although we intend to
seek stockholder approval at our 2004 annual meeting of an amendment that will
eliminate the classification of the Board of Directors. The issuance of
preferred stock and the existence of a classified board of directors could have
the effect of delaying, deterring or preventing a change in control.
Section 203 of the Delaware General Corporation Law generally prohibits
a public Delaware corporation from engaging in a "business combination" with an
"interested stockholder" for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the
business combination is approved in a prescribed manner. "Business combination"
is defined to include mergers, asset sales and other specified transactions
resulting in a financial benefit to the interested stockholder. An "interested
stockholder" is defined as a person who, together with affiliates and
associates, owns (or, within the prior three years, did own) 15% or more of a
corporation's voting stock. Section 203 may discourage transactions in which our
stockholders might otherwise receive a premium for their shares over the then
current price and may limit our stockholders' ability to approve transactions
even if they believe the transaction is in their best interests.
ITEM 2. PROPERTIES
We lease approximately 26,000 square foot facility in Ventura,
California. In addition to our corporate offices, the facility includes space
for the following:
o a research and development laboratory equipped with assembly and test
equipment for concept modeling and product development;
o a machine shop equipped with tools for the fabrication of new product
parts for concept modeling and assembly; and
o a 3,120 square foot class 100,000 clean room used for the assembly of
prototypes.
Our annual lease payments for this facility are approximately $182,131
and the lease expires on October 31, 2008.
ITEM 3. LEGAL PROCEEDINGS
There are no legal proceedings pending or, to the knowledge of
management, threatened against us.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
16
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock trades on the Nasdaq National Market under the symbol
"MEDC." Set forth below are the high and low sales prices of our common stock,
as reported by Nasdaq, during each of the quarterly periods in 2002 and 2003.
Market Information
Fiscal year ended December 31, 2002 High Low
- ----------------------------------- ------- -------
First Quarter.................................................... $ 27.20 $ 11.60
Second Quarter................................................... 17.19 9.82
Third Quarter.................................................... 12.99 3.03
Fourth Quarter................................................... 8.26 3.10
Fiscal year ended December 31, 2003 High Low
- ----------------------------------- ------- ------
First Quarter.................................................... $ 10.13 $ 2.90
Second Quarter................................................... 5.29 2.90
Third Quarter.................................................... 5.62 3.69
Fourth Quarter................................................... 4.50 3.25
Holders
As of February 25, 2004, we estimate that we had approximately 121
holders of record of our common stock. We believe that the number of beneficial
holders of our stock is greater.
Dividends
We do not anticipate paying any cash dividends in the foreseeable
future. We currently intend to retain any future earnings for use in our
business.
17
ITEM 6. SELECTED FINANCIAL DATA
The following data should be read in conjunction with the "Management's
Discussion and Analysis of Financial Condition and Results of Operations" and
the financial statements and related notes included elsewhere in this Form 10-K.
2003 2002 2001 2000 1999
- -------------------------------------------------------------------------------------------------------
Year ended:
Revenue............... $ 826,725 $ 474,325 $ 2,330,000 $ 4,128,993 $ --
Net loss.............. (6,046,489) (8,081,061) (4,026,991) (2,793,365) (4,247,473)
Dividends on Series A
preferred stock..... -- -- -- 150,000 --
Net loss per common
Share............... $ (0.42) $ (0.67) $ (0.38) $ (0.30) $ (0.53)
At:
Total assets.......... $28,546,429 $16,989,224 $ 8,259,960 $ 8,565,573 $ 7,257,286
Debt.................. 1,506 4,080 16,806 20,895 1,073,797
- -------------------------------------------------------------------------------------------------------
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Overview
We consider the following to be the most important matters on which
management focuses in evaluating our operating performance and financial
condition.
Revenue Growth. We believe that revenue growth is the key factor
affecting our results of operations. Our revenues have historically consisted of
royalties and up-front licensing fees. In 2003, we also recognized revenues in
connection with sales of our 1Shot Safety Dental Syringe. Our arrangement
regarding the sale of the 1Shot Safety Dental Syringe, under which we have
contracted for manufacture and distribution of the product, but have not
transferred our intellectual property rights, provides greater potential for per
unit revenues than would be the case if the product was licensed. Nevertheless,
we believe our short term revenue growth will largely be dependent on the
efforts of BD in selling products incorporating technology licensed from us. The
extent to which BD commits its resources to the sale of these products is
entirely within BD's control. Management has been disappointed with the pace of
commercialization of these products in the past, and has encouraged BD to
accelerate its efforts. In this regard, although license revenues from BD have
increased, all of such revenues constitute minimum royalties. However, we are
encouraged by BD's launch of the BD Vacutainer(TM) Push Button Collection Set in
June 2003 and the 1 ml version of the Integra Syringe in February 2004 in
addition to the growth in sales of the 3 ml Integra Syringe in 2003.
Management also is focused on increasing revenues by seeking to license
additional products that are not currently subject to licenses, by entering into
additional collaborative arrangements and possibly by acquiring complimentary
businesses.
We rely on our licensees to provide us with sales information in order
to calculate the royalties due to us as a result of those sales. While we have
to date relied on this sales information without independent verification, we
are currently developing appropriate procedures to verify this information in
the future.
18
Liquidity. We have historically generated cash principally from
issuances of equity and up-front licensing fees. Although we believe that our
cash derived from these sources is sufficient to support ongoing operations for
at least the next twelve months, our ultimate success depends on our ability to
generate revenues to support operations. If we cannot generate sufficient
revenues to support operations, we will likely have to rely upon debt or equity
financing. There is no assurance we will be able to obtain such financing.
Results of Operations
Year Ended December 31, 2003 Compared to Year Ended December 31, 2002
Total revenue in 2003 was $826,725 compared to revenue of $474,325 in
2002. Revenue in 2003 reflected the sales of the 1Shot Safety Dental Syringe as
well as royalty payments under our licensing agreements, including $445,701 in
minimum royalty payments from BD and Enpath Medical, Inc. Revenue in 2002 also
reflected royalty payments from the sale of our licensed products.
General and administrative expenses were $5,927,713 in 2003, a decrease
of $674,707 as compared to general and administrative expenses of $6,602,420 in
2002. The decrease was primarily due to a reduction of expenditures for employee
compensation of approximately $227,000 resulting from a reduction in staff,
legal expenses of approximately $266,000, professional costs of approximately
$125,000 and stock based compensation of approximately $309,000 resulting from
the issuance of options, restricted stock grants and warrants, offset by an
increase in bad debt expense of $250,000.
Research and development expenses for the year ended December 31, 2003
were $1,484,891, a decrease of $484,818 as compared to research and development
expenses of $1,969,709 for the corresponding period in 2002. The decrease is
partially attributable to a $350,000 charge recorded in December 2002 resulting
from the settlement of a claim by our former Director of Research and
Development and consulting costs of approximately $96,000 in 2002 related to the
implementation of a quality program required for companies engaged in the
manufacture of product.
Investment income was $693,765 in 2003, an increase of $344,561 as
compared to $349,204 in the corresponding period in 2002. The increase was due
primarily to an increase of approximately $11,000,000 in invested cash in 2003.
In 2002, we recorded an impairment charge on our investment in Enpath
Medical Inc. (formerly Medamicus) of $331,419.
Year Ended December 31, 2002 Compared to Year Ended December 31, 2001
Total revenue in 2002 was $474,325 compared to revenue of $2,330,000 in
2001. Revenue in 2002 consisted of royalty payments from the sale of our
licensed products. Revenue in 2001 consisted principally of an up-front license
payment from Enpath Medical Inc. (formerly Medamicus) for our license of the
Safety Seldinger Introducer Needle for use in arterial access.
General and administrative expenses were $6,602,420 in 2002, an
increase of $1,100,033 as compared to general and administrative expenses of
$5,502,387 in 2001. The increase was primarily due to an increase of
approximately $455,000 in employee compensation related to the hiring of a Chief
Operating Officer, additional administrative personnel, legal expenses of
approximately $375,000 related to the resolution of the royalty rate dispute
with BD and professional costs of approximately $234,000.
Research and development expenses for the year ended December 31, 2002
were $1,969,709, an increase of $896,386 as compared to research and development
expenses of $1,073,323 for the corresponding period in 2001. The increase was
primarily due to a charge of $350,000 recorded in December 2002 resulting from
the settlement of a claim by our former Director of Research and Development, an
increase in employee compensation cost of approximately $214,000 to support
research and development, regulatory application costs of approximately $128,000
associated with the Dental Pre-filled Cartridge Injector and costs of
approximately $200,000 associated with the development of new products.
19
In accordance with FAS No. 115, "Accounting for Certain Investments in
Debt and Equity Securities", and consistent with the Company's accounting policy
for marketable equity securities, in the fourth quarter of fiscal 2002, the
Company determined that the decline in the fair value of its investment in
Medamicus stocks (which was received as part of a development and licensing
agreement in 2001) was other-than-temporary. Accordingly, the Company
established a new basis of $448,078 in the investment equivalent to its fair
market value at December 31, 2002. As a result, the Company realized a loss of
$331,419 or ($0.03) per basic and diluted common share.
Liquidity and Capital Resources
In 2003, our principal sources of cash were the net proceeds of
approximately $16,000,000 from our August 2003 private placement of common
stock, the $2,241,329 of cash generated from our sale of Enpath Medical Inc.
common stock, licensing fees of $253,069 and $76,329 from the sale of products.
In 2002, our principal source of cash was the net proceeds of approximately
$14,200,000 from our March 2002 private placement of common stock.
Our primary uses of cash in 2003 consisted of general and
administrative costs, including cash payments of $2,115,645 for salaries and
research and development costs and $439,371 to purchase automated equipment and
molds necessary for Owens-Illinois to manufacture the 1Shot Safety Dental
Cartridge Syringe. General and administrative costs in 2002 included cash
payments of $2,687,661 for salaries and research and development costs.
At December 31, 2003, we had a revolving line of credit under which we
may borrow up to $3,000,000. This facility can be used to fund working capital
needs and finance capital equipment purchases. Advances for capital equipment
financing may not exceed $600,000 and borrowings would be collateralized by
substantially all of our assets. Any borrowings to meet working capital needs
would bear interest at LIBOR plus 2.25%, while borrowings to finance capital
equipment purchases would bear interest at the prime rate plus 2.5%. The
facility expires on May 31, 2004, and there is no assurance that we will be
successful in negotiating a continuation of the availability of the line of
credit or the terms that will be made available to us. There were no amounts
outstanding under the agreement at December 31, 2003.
At December 31, 2003, we had cash, cash equivalents and available for
sale securities of $25,029,749 as compared to $14,165,300 at 2002. We believe
that we have sufficient funds to support our planned operations for at least the
next twelve months. The availability of resources over a longer term will be
dependent on our ability to enter into licensing agreements, the amount of
royalty payments we receive from our current and future licensees, our ability
to enter into and profitably operate under collaborative arrangements, and our
ability to raise additional equity or debt financing. We have not generated
sufficient cash flows from operations to support our operations on an on-going
basis and anticipate that we may need to seek additional sources of funding in
the future. If we are unsuccessful in negotiating additional agreements, or if
licensing revenues are insufficient to support our operations, we may be
required to reduce the scope of, or cease, our operations.
Contractual Obligations
Our contractual obligations as of December 31, 2003 consist of the
following:
Payments due by period
------------------------------------------------------------------------
Total Less than 1 year 1-3 years 3-5 years
------------------------------------------------------------------------
Capital lease obligations 1,506 1,506 - -
Operating lease obligations 911,209 185,104 353,086 373,019
------------------------------------------------------------------------
Total $912,715 $186,610 $ 353,086 $ 373,019
========================================================================
20
During 2003, we renewed our lease for office space in Ventura,
California. The renewal is for five years beginning November 1, 2003 and
terminating October 31, 2008. The base rent of $15,310 per month will be
increased annually by 3%.
Critical Accounting Policies and Estimates
In preparing our financial statements, we are required to make
estimates and assumptions that, among other things, affect the reported amounts
of assets and liabilities and reported amounts of revenues and expenses. These
estimates and assumptions are most significant where they involve levels of
subjectivity and judgment necessary to account for highly uncertain matters or
matters susceptible to change, and where they can have a material impact on our
financial condition and operating performance. We discuss below the more
significant estimates and related assumptions used in the preparation of our
consolidated financial statements. If actual results were to differ materially
from the estimates made, the reported results could be materially affected.
Patents. The Company capitalizes costs incurred in connection with
patent acquisitions, patent applications and patent defenses. These costs are
amortized using the straight line method over the estimated useful life of the
patents, not to exceed the legal life. The carrying value of the patents are
regularly reviewed by management and impairments, if any, are recognized when
the expected future cash flows derived from the patent is less than the carrying
value. The estimates of useful lives of the patents and expected future cash
flows are based on a number of factors including product demand, market
conditions, technology developments and the activities of our competitors. If
future events or evaluations cause management to conclude that the value of one
or more patents is impaired, we may recognize significant losses, and our
financial condition may be negatively affected, in the future.
Available for Sale Securities. Available-for-sale securities are
reported at a fair value, based on quoted market prices, with the net unrealized
gain or loss reported as a component of "Accumulated other comprehensive income
(loss)" in stockholders' equity.
We record an impairment charge when we believe an investment has
experienced a decline in value that is other-than-temporary. In determining if a
decline in market value below cost for a publicly traded security is
other-than-temporary, we evaluate the relevant market conditions, offering
prices, trends of earnings, price multiples and other key measures. When a
decline in value is deemed to be other-than-temporary, we recognize an
impairment loss in the current period to the extent of the decline below the
carrying value of the investment. Adverse changes in market conditions or poor
operating results of underlying investments could result in additional
other-than-temporary losses in future periods. Moreover, if management's
evaluation is not correct, we may recognize significant impairment losses in
later periods.
New Accounting Standards
In July 2003, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 150. This Statement
establishes standards for how to classify and measure certain financial
instruments with characteristics of both liabilities and equity. It requires the
classification of a financial instrument that is within its scope as a
liability. This Statement is effective for instruments entered into or modified
after May 31, 2003. The adoption of this pronouncement will not impact our
financial position or results of operations.
In January 2003, the FASB issued Interpretation No. 46 or FIN 46,
"Consolidation of Variable Interest Entities", an interpretation of Accounting
Research Bulletin No. 51, "Consolidated Financial Statements". FIN 46
establishes accounting guidance for consolidation of variable interest entities
that function to support the activities of the primary beneficiary. In October
2003, the FASB issued FASB Staff Position FIN 46-6, "Effective Date of FASB
Interpretation No. 46, Consolidation of Variable Interest Entities" deferring
the effective date for applying the provisions of FIN 46 for public entities'
interests in variable interest entities or potential variable interest entities
created before February 1, 2003 until financial statements of interim or annual
periods that end after December 15, 2003. In December 2003, the FASB issued FIN
46 (revised December 2003), "Consolidation of Variable Interest Entities." This
revised interpretation is effective for all entities no later than the end of
the first reporting period that ends after March 15, 2004. We have no investment
in or contractual relationship or other business relationship with a variable
interest entity and therefore the adoption of this interpretation will not have
any impact on our consolidated financial position or results of operations.
However, if we enter into any such arrangement with a variable interest entity
in the future or an entity with which we have a relationship is reconsidered
based on guidance in the revised interpretation to be a variable interest
entity, our consolidated financial position or results of operations might be
impacted.
21
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There were no amounts outstanding under our revolving line of credit at
December 31, 2003. If we were to borrow under our credit facility, borrowings to
meet working capital needs would bear interest at LIBOR plus 2.25% and
borrowings to finance capital equipment purchases would bear interest at the
prime rate plus 2.5%. As a result, any such borrowings would be subject to
interest rate fluctuations which could increase our interest expense,
respectively.
We invest a portion of excess cash in marketable securities in
accordance with our investment guidelines as approved by our Board of Directors.
These investments are in highly liquid, low risk securities where our risk of
loss is at a minimum.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Incorporated by reference from the consolidated financial statements
and notes thereto of Med-Design which are attached hereto beginning on page F-1.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
ITEM 9A. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
Management, with the participation of our Chief Executive Officer and
Chief Financial Officer, evaluated the effectiveness of our disclosure controls
and procedures as of the end of the period covered by this report. Based on that
evaluation, the Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures as of the end of the period covered
by this report are functioning effectively to provide reasonable assurance that
the information required to be disclosed by the Company in reports filed under
the Securities Exchange Act of 1934 is recorded, processed, summarized and
reported within the time periods specified in the SEC's rules and forms. A
controls system, no matter how well designed and operated, cannot provide
absolute assurance that the objectives of the controls system are met, and no
evaluation of controls can provide absolute assurance that all control issues
and instances of fraud, if any, within a company have been detected.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting occurred
during the fourth fiscal quarter of the period covered by this report that has
materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
22
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
This information will be included in an amendment to this Form 10-K,
which will be filed within 120 days after the close of our fiscal year covered
by this report.
ITEM 11. EXECUTIVE COMPENSATION
This information will be included in an amendment to this Form 10-K,
which will be filed within 120 days after the close of our fiscal year covered
by this report.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
This information will be included in an amendment to this Form 10-K,
which will be filed within 120 days after the close of our fiscal year covered
by this report.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
This information will be included in an amendment to this Form 10-K,
which will be filed within 120 days after the close of our fiscal year covered
by this report.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
This information will be included in an amendment to this Form 10-K,
which will be filed within 120 days after the close of our fiscal year covered
by this report.
23
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) Documents filed as part of this Report:
1. Financial Statements. The following financial statements and notes
thereto of Med-Design which are attached hereto beginning on page F-1, have been
incorporated by reference into Item 8 of this Report on Form 10-K:
Page
----
Report of Independent Auditors F-2
Consolidated Balance Sheets as of December 31, 2003 and 2002 F-3
Consolidated Statements of Operations for years ended
December 31, 2003, 2002 and 2001 F-4
Consolidated Statements of Stockholders' Equity and Comprehensive
Loss for the years ended December 31, 2003, 2002 and 2001 F-5
Consolidated Statements of Cash Flows for the years ended
December 31, 2003, 2002 and 2001 F-6
Notes to Consolidated Financial Statements F-7
2. All schedules are omitted because they are inapplicable, or not
required, or the information is shown in the financial statements or notes
thereto.
3. List of Exhibits. The following is a list of exhibits filed as part
of this annual report on Form 10-K. Where so indicated by footnote, exhibits
which were previously filed are incorporated by reference.
24
Exhibit
Number Description
------ -----------
3.1 (1) Certificate of Incorporation of Med-Design.
3.2 (8) Certificate of Amendment to Certificate of Incorporation of
Med-Design.
3.3 (1) Bylaws of Med-Design.
4.1 (1) Specimen of Common Stock Certificate of Med-Design.
10.1 (4) Amended and Restated Non-Qualified Stock Option Plan.
10.2 (2) Lease Agreement dated June 15, 1995 between Moen Development
and MDC Research Ltd. and guaranteed by Med-Design.
10.3 Renewal Lease Agreement dated November 1, 2003, Moen
Development and MDC Research Ltd.**
10.8 (4) Licensing and Option Agreement dated December 11, 1998 with
Becton, Dickinson and Company.
10.9 (4) Equity agreement dated December 11, 1998 with Becton, Dickinson
and Company.
10.10 (5) Addendum to License Agreement dated December 11, 1999 with
Becton, Dickinson and Company.
10.11 (5) Warrant dated March 5, 1999 between Med-Design and
Joseph Bongiovanni.*
10.12 (5) Second Addendum to License Agreement dated January 25, 2000
with Becton, Dickinson and Company.
10.13 (6) Warrant Agreement dated April 25, 2000 between Med-Design and
Lawrence Ellis.*
10.15 (6) Licensing Agreement dated May 11, 2000 with Becton, Dickinson
and Company.
10.16 (7) 2001 Equity Compensation Plan.
10.17 Employment Agreement dated October 10, 2002 between Med-Design
and James Donegan.
10.18 Employment Agreement dated October 10, 2002 between Med-Design
and Joseph Bongiovanni.
10.19 Employment Agreement dated October 10, 2002 between Med-Design
and Lawrence D. Ellis.
10.20 Employment Agreement dated May 15, 2002 between Med-Design and
David Dowsett
10.21 Employment Agreement extension dated October 17, 2003 between
Med-Design and David Dowsett
21.1 List of Subsidiaries of Med-Design.
23.1 Consent of PricewaterhouseCoopers LLP.**
31.1 Certificate of the Chief Executive Officer required by
Rule 15d - 14(a). **
31.2 Certificate of the Chief Financial Officer required by
Rule 15d - 14(a). **
32.1 Certificate of the Chief Executive Officer required by
Rule 15d - 14(b). **
32.2 Certificate of the Chief Financial Officer required by
Rule 15d - 14(b). **
99.1 Experts**
- -----------------------
* Constitutes management contract or compensatory plan or arrangement
required to be filed as an exhibit to this Form 10-K
** Filed herewith
(1) Incorporated by reference to Form SB-2 filed April 7, 1995 and
Amendment Nos. 1, 2 and 3 thereto (File No. 33-901014).
(2) Incorporated by reference to Form 10-KSB filed on March 29, 1996.
(3) Incorporated by reference to Form 10-KSB filed on March 31, 1998.
25
(4) Incorporated by reference to Form 10-KSB filed on March 31, 1999.
(5) Incorporated by reference to Form 10-KSB filed on March 7, 2000.
(6) Incorporated by reference to Form 10-K filed March 23, 2001.
(7) Incorporated by reference to Schedule 14A filed on June 28, 2001.
(8) Incorporated by reference to Form 10-K filed April 1, 2002.
(b) Reports on Form 8-K
We did not file any reports on Form 8-K during the last quarter of the
period covered by this report.
26
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
THE MED-DESIGN CORPORATION
Date: March 10, 2004 By: James M. Donegan
----------------
James M. Donegan
President and Chief
Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Title Date
- --------- ----- ----
James M. Donegan Chairman of the Board, President and Chief March 8, 2004
- --------------------------------- Executive Officer (Principal Executive Officer)
James M. Donegan
Lawrence D. Ellis Vice President, Finance and Chief Financial March 8, 2004
- --------------------------------- Officer (Principal Financial Officer and Principal
Lawrence D. Ellis Accounting Officer)
Joseph N. Bongiovanni, III Director March 8, 2004
- ---------------------------------
Joseph N. Bongiovanni, III
D. Walter Cohen Director March 8, 2004
- ---------------------------------
D. Walter Cohen
Pasquale L. Vallone Director March 8, 2004
- ---------------------------------
Pasquale L. Vallone
Gilbert M. White Director March 8, 2004
- ---------------------------------
Gilbert M. White
Ralph Balzano Director March 8, 2004
- ---------------------------------
Ralph Balzano
Vincent J. Papa Director March 8, 2004
- ---------------------------------
Vincent J. Papa
James E. Schleif Director March 8, 2004
- ---------------------------------
James E. Schleif
Stephen E. Smith, Jr. Director March 8, 2004
- ---------------------------------
Stephen E. Smith, Jr.
Paul Castignani Director March 8, 2004
- ---------------------------------
Paul Castignani
Index to Consolidated Financial Statements
Page
----
Report of Independent Auditors.............................................................. F-2
Consolidated Balance Sheets as of December 31, 2003 and 2002 ............................... F-3
Consolidated Statements of Operations for years ended F-4
December 31, 2003, 2002 and 2001.......................................................
Consolidated Statements of Stockholders' Equity and Comprehensive Loss for the years F-5
ended December 31, 2003, 2002 and 2001.................................................
Consolidated Statements of Cash Flows for the years ended F-6
December 31, 2003, 2002 and 2001.......................................................
Notes to Consolidated Financial Statements.................................................. F-7 to F-22
F-1
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
REPORT OF INDEPENDENT AUDITORS
To the Board of Directors and Stockholders of
The Med-Design Corporation:
In our opinion, the consolidated financial statements listed in the index
appearing under item 15(a) (1) on page 24 present fairly, in all material
respects, the financial position of The Med-Design Corporation and its
subsidiaries (the Company) at December 31, 2003 and 2002, and the results of
their operations and their cash flows for each of the three years in the period
ended December 31, 2003 in conformity with accounting principles generally
accepted in the United States of America. These financial statements are the
responsibility of the Company's management; our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our
audits of these statements in accordance with auditing standards generally
accepted in the United States of America, which require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for our opinion.
PricewaterhouseCoopers LLP
Philadelphia, PA
March 5, 2004
F-2
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31, December 31,
2003 2002
------------ ------------
ASSETS
Current Assets:
Cash and cash equivalents.......................................................... $ 5,198,837 $ 1,917,130
Available-for-sale securities...................................................... 19,830,912 12,248,170
Trade receivables.................................................................. 655,056 143,587
Prepaid expenses and other current assets.......................................... 305,004 420,590
------------ ------------
Total current assets............................................................ 25,989,809 14,729,477
Note receivable - related party.................................................... -- 250,000
Property, plant, and equipment, net................................................ 782,872 345,130
Patents, net of accumulated amortization of $843,134 and $659,144
at December 31, 2003 and December 31, 2002, respectively........................ 1,773,748 1,664,617
------------ ------------
Total Assets....................................................................... $ 28,546,429 $ 16,989,224
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion capital lease obligations.......................................... $ 1,506 $ 2,574
Accounts payable................................................................... 451,110 290,775
Accrued compensation and benefits.................................................. 162,740 513,021
Accrued professional fees.......................................................... 138,950 100,000
Other accrued expenses............................................................. 27,466 43,512
------------ ------------
Total current liabilities....................................................... 781,772 949,882
Capital lease obligations, less current maturities................................. -- 1,506
------------ ------------
Total liabilities............................................................... 781,772 951,388
------------ ------------
Commitments and Contingencies (Note 7)
Stockholders' equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized; No shares
issued and outstanding as of December 31, 2003 and 2002,
respectively.................................................................... -- --
Common stock, $.01 par value, 30,000,000 shares authorized; 16,572,390 and
12,519,798 shares issued and outstanding at
December 31, 2003 and 2002, respectively........................................ 165,724 125,198
Additional paid-in capital......................................................... 71,033,777 53,083,149
Accumulated deficit................................................................ (43,279,731) (37,233,242)
Accumulated other comprehensive (loss) income...................................... (155,113) 62,731
------------ ------------
Total stockholders' equity............................................................. 27,764,657 16,037,836
------------ ------------
Total Liabilities and Stockholders' Equity............................................. $ 28,546,429 $ 16,989,224
============ ============
The accompanying notes are an integral part of these financial statements.
F-3
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31,
2003 2002 2001
----------- ----------- ------------
Revenue................................................ $ 826,725 $ 474,325 $ 2,330,000
----------- ----------- ------------
Operating expense:.....................................
Product costs..................................... 153,953 -- --
General and administrative........................ 5,927,713 6,602,420 5,502,387
Research and development.......................... 1,484,891 1,969,709 1,073,323
----------- ----------- ------------
Total operating expenses.......................... 7,566,557 8,572,129 6,575,710
Loss from operations................................... (6,739,832) (8,097,804) (4,245,710)
Interest expense....................................... (422) (1,042) (10,645)
Investment income...................................... 693,765 349,204 229,364
Realized loss on investments........................... -- (331,419) --
----------- ----------- ------------
Net loss............................................... ($6,046,489) ($8,081,061) ($4,026,991)
=========== =========== ============
Basic and diluted loss per common share ............... ($ 0.42) ($0.67) ($0.38)
Weighted average common shares outstanding............. 14,282,613 12,116,143 10,666,754
The accompanying notes are an integral part of these financial statements.
F-4
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
AND COMPREHENSIVE LOSS
Unrealized
Gains &
Loss On
Additional Available-
Preferred Common Paid-In Accumulated For-Sale Stockholders'
Shares Amount Shares Amount Capital Deficit Securities Equity
--------- ------ ---------- -------- ----------- ------------ ---------- ------------
Balance, December 31, 2000......... -- $ -- 10,541,320 $105,413 $32,974,466 ($25,125,190) $ 25,919 $ 7,980,608
Issuance of common stock in
connection with exercise of
stock options and warrants.... 422,066 4,221 2,102,778 2,106,999
Stock based compensation........... 1,792,082 1,792,082
Change in unrealized gains
(loss) on available-for-sale-
securities .................... 30,861 30,861
Net loss......................... (4,026,991) (4,026,991)
--------- ------ ---------- -------- ----------- ------------ ---------- ------------
Balance December 31, 2001.......... -- $ -- 10,963,386 $109,634 $36,869,326 ($29,152,181) $ 56,780 $ 7,883,559
Issuance of common stock in
connection with exercise of
stock options and warrants .... 103,784 1,038 252,046 253,084
Issuance of common stock in
connection with private
placement, net................. 1,326,260 13,262 14,179,178 14,192,440
Issuance of stock in
connection with employment
agreements..................... 126,368 1,264 (1,264) --
Stock based compensation......... 1,783,863 1,783,863
Change in unrealized gains
(loss) on Available-for-sale-
securities .................... 5,951 5,951
Net loss......................... (8,081,061) (8,081,061)
--------- ------ ---------- -------- ----------- ------------ ---------- ------------
Balance December 31, 2002.......... -- $ -- 12,519,798 $125,198 $53,083,149 ($37,233,242) $ 62,731 $ 16,037,836
--------- ------ ---------- -------- ----------- ------------ ---------- ------------
Issuance of common stock in
connection with exercise of
stock options and warrants..... 320,900 3,209 594,590 597,799
Issuance of common stock in
connection with private
placement, net................. 3,598,844 35,989 15,874,080 15,910,069
Issuance of stock in
connection with employment
agreements .................... 126,368 1,263 (1,263) --
Issuance of stock in
connection with private
investor loan ................. 6,480 65 (65)
Stock based compensation......... 1,483,286 1,483,286
Change in unrealized gains
(loss) on Available-for-sale-
securities .................... (217,844) (217,844)
Net loss......................... (6,046,489) (6,046,489)
--------- ------ ---------- -------- ----------- ------------ ---------- ------------
Balance December 31, 2003.......... -- $ -- 16,572,390 $165,724 $71,033,777 ($43,279,731) ($155,113) ($27,764,657)
========= ====== ========== ======== =========== ============ ========== ============
[RESTUBBED TABLE]
Comprehensive
Income (Loss)
------------
Balance, December 31, 2000......... ($2,797,406)
Issuance of common stock in
connection with exercise of
stock options and warrants....
Stock based compensation...........
Change in unrealized gains
(loss) on available-for-sale-
securities .................... 30,861
Net loss......................... (4,026,991)
------------
Balance December 31, 2001.......... ($3,996,130)
Issuance of common stock in
connection with exercise of
stock options and warrants ....
Issuance of common stock in
connection with private
placement, net.................
Issuance of stock in
connection with employment
agreements.....................
Stock based compensation.........
Change in unrealized gains
(loss) on Available-for-sale-
securities .................... 5,951
Net loss......................... (8,081,061)
------------
Balance December 31, 2002.......... ($8,075,110)
------------
Issuance of common stock in
connection with exercise of
stock options and warrants.....
Issuance of common stock in
connection with private
placement, net.................
Issuance of stock in
connection with employment
agreements ....................
Issuance of stock in
connection with private
investor loan .................
Stock based compensation.........
Change in unrealized gains
(loss) on Available-for-sale-
securities .................... (217,844)
Net loss......................... (6,046,489)
------------
Balance December 31, 2003.......... ($6,264,333)
============
The accompanying notes are an integral part of these financial statements.
F-5
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
2003 2002 2001
------------ ------------ -----------
Cash flows from operating activities:
Net loss........................................... ($6,046,489) ($8,081,061) ($4,026,991)
Adjustments to reconcile net loss to cash used in
operating activities:
Depreciation and amortization................ 420,333 511,307 350,514
Loss (gain) from sale of available-for-sale
securities................................. (166,830) (46,375) --
Default of related party note................ 250,000 -- --
Realized loss on available-for-sale securities -- 331,419 --
Changes in operating assets and liabilities:
Prepaid expenses and other current assets.... (119,059) (274,376) 11,073
Trade receivable............................. (511,468) -- --
Stock-based compensation..................... 1,483,286 1,783,863 1,792,082
Common stock received as licensing fee....... -- -- (1,000,000)
Accounts payable........................... 160,335 92,634 (118,466)
Accrued expenses........................... (327,377) 495,079 (86,009)
----------- ----------- -----------
Net cash used in operating activities........ (4,857,269) (5,187,510) (3,077,797)
----------- ----------- -----------
Cash flows from investing activities:
Purchase of property and equipment............. (439,371) (292,084) (18,749)
Additions to patents........................... (293,191) (148,577) (209,001)
Notes receivable - related party............... -- (525,000) --
Repayment of Note receivable - related party... -- 275,000 --
Investments in available-for-sale securities... (16,579,932) (12,125,034) (1,570,600)
Sale of available-for-sale securities.......... 8,946,176 5,089,772 1,442,899
----------- ----------- -----------
Net cash used in investing activities........ (8,366,318) (7,725,923) (355,451)
----------- ----------- -----------
Cash flows from financing activities:
Capital lease payments......................... (2,574) (12,726) (4,087)
Warrants and stock options exercised........... 597,799 253,084 2,106,997
Proceeds from private placement, net........... 15,910,069 14,192,440 --
----------- ----------- -----------
Net cash provided by financing activities.... 16,505,294 14,432,798 2,102,910
----------- ----------- -----------
Increase (decrease) in cash and cash equivalents... 3,281,707 1,519,365 (1,330,338)
Cash and cash equivalents, beginning of period..... 1,917,130 397,765 1,728,103
----------- ----------- -----------
Cash and cash equivalents, end of period........... $ 5,198,837 $ 1,917,130 $ 397,765
=========== =========== ===========
Cash paid during the period:
Interest paid.................................. $ 422 $ 1,042 $ 10,645
Non-cash investing and financing activities:
Change in unrealized (loss) gain on
available-for-sale securities................ (217,844) 5,951 30,861
Advances for purchase of fixed assets transferred
from Prepaid Assets to Property and Equipment 234,645 -- --
The accompanying notes are an integral part of these financial statements.
F-6
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Nature of Business
The Med-Design Corporation ("Med-Design" or the "Company") is
principally engaged in the design, development and licensing of safety medical
devices intended to reduce the incidence of accidental needlesticks. Each safety
medical device we design and develop incorporates our proprietary needle
retraction technology. Our technology enables health care professionals to
retract a needle into the body of the medical device for safe disposal without
any substantial change in operating technique. Med-Design's product technology
generally can be categorized into the following five groups: hypodermic syringes
used to inject drugs and other fluids into the body; fluid collection devices
used to draw blood or other fluids from the body; infusion therapy devices used
to provide access to patients' vessels; and specialty safety devices for needle
based and other applications.
2. Significant Accounting Policies
Principles of Consolidation:
- ----------------------------
The accompanying consolidated financial statements include the accounts
of The Med-Design Corporation and its wholly owned subsidiaries, MDC Investment
Holdings, Inc. and MDC Research Ltd. All significant intercompany accounts and
transactions have been eliminated in consolidation. Certain amounts from prior
years have been reclassified for comparability.
Cash and Cash Equivalents:
- --------------------------
Med-Design considers all bank depository cash accounts with initial
maturities of less than three months to be cash equivalents.
Concentrations of Credit Risk:
- ------------------------------
Financial instruments which potentially subject Med-Design to
concentration of credit risk, consist principally of cash and
available-for-sale-securities. At times, Med-Design's cash balances exceed FDIC
insurance limits. The Company invests cash balances in financial institutions
with high credit ratings.
Med-Design invests in high credit quality financial instruments and,
through diversification, attempts to limit the extent of credit exposure on
available-for-sale-securities.
Available-for-Sale-Securities:
- ------------------------------
Med-Design's investments are classified as available-for-sale
securities and accordingly, any unrealized holding gains or losses, net of
taxes, are excluded from income and recognized as a separate component of
stockholders' equity until realized. Investments in marketable securities are
made consistent with Med-Design's investment guidelines as developed by
management and approved by the Board of Directors. Available-for-sale securities
are reported at fair value, based on quoted market prices, with the net
unrealized gain or loss reported as a component of "Accumulated other
comprehensive income (loss)" in stockholders' equity.
The Company records an impairment charge when it believes an investment
has experienced a decline in value that is other-than-temporary. In determining
if a decline in market value below cost for a publicly traded security is
other-than-temporary, the Company evaluates the relevant market conditions,
offering prices, trends of earnings, price multiples and other key measures.
When a decline in value is deemed to be other-than-temporary,
F-7
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
2. Significant Accounting Policies, continued
the Company recognizes an impairment loss in the current period to the extent of
the decline below the carrying value of the investment. Adverse changes in
market conditions or poor operating results of underlying investments could
result in additional other-than-temporary losses in future periods.
Property, Plant and Equipment:
- ------------------------------
Property, plant and equipment are carried at cost. Assets held under
capital lease are recorded at the lower of the net present value of the minimum
lease payments or the fair value of the leased assets at the inception of the
lease, whichever is lower. Significant additions or improvements extending the
assets' useful lives are capitalized.
When property, plant and equipment are sold, retired or otherwise
disposed of, the applicable costs and accumulated depreciation are removed from
the accounts and the resulting gain or loss recognized.
Depreciation is computed by the straight-line method utilizing rates
based upon the estimated service life of the various classes of assets.
Leasehold improvements are depreciated over the remaining lease term or asset
life if shorter.
Recoverability of Long-Lived Assets:
- ------------------------------------
Med-Design's assets are reviewed for impairment whenever events or
circumstances provide evidence that suggest that the carrying amount may not be
recoverable. When necessary, Med-Design assesses the recoverability of its
assets by determining whether the carrying value can be recovered through
projected undiscounted future cash flows.
Patents:
- --------
Patents, patent applications, and patent rights are stated at
acquisition costs. Amortization of patents is recorded by the straight-line
method over the estimated useful lives of the patents, not to exceed the legal
life. Patent amortization expense for the years ended December 31, 2003, 2002
and 2001 was $184,058, $172,536, and $191,579, respectively. The estimated
aggregate amortization expense for 2004 through 2009 is $194,550 per year.
Revenue Recognition:
- --------------------
Fees received in connection with the entry into licensing contracts for
the Company's patented, proprietary products are recorded as revenue following
the execution of a binding agreement, and when the Company has fulfilled its
obligations under the arrangement or when Med-Design's only remaining obligation
is to maintain and defend the licensed patent rights.
Royalties received on licensed products which are based on the
licensee's product volume are recorded as revenue in the period when the royalty
payments are earned. Minimum contractual royalty payments related to licensed
products are recorded as revenue during the period to which the minimum payments
relate.
Revenues from the sale of contract manufactured products are recorded
upon the receipt of the product by customer.
Income Taxes:
- -------------
Med-Design accounts for income taxes under the asset and liability
method in accordance with Statement of Financial Accounting Standards No. 109,
"Accounting for Income Taxes". Deferred tax assets and liabilities are
recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and
their respective tax bases. Deferred tax assets and liabilities are
F-8
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
2. Significant Accounting Policies, continued
measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. A valuation allowance is recorded for deferred tax assets where it
appears more likely than not that the Company will not be able to recover the
deferred tax asset.
Research and Development:
- -------------------------
Expenditures relating to the development of new products and processes,
including significant improvements and refinements to existing products, are
expensed as incurred.
Stock Based Compensation:
- -------------------------
The Company applies Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" ("APB 25") and the Financial
Accounting Standards Board Interpretation No. 44 "Accounting for Certain
Transactions Involving Stock Compensation" in accounting for its stock plans.
The Company has adopted the disclosure only provisions of Statement of Financial
Accounting Standards No. 123, "Accounting for Stock-Based Compensation" ("SFAS
123"). Had compensation expense for Med-Design's Stock Option Plan and warrant
grants been recorded based on the fair value of the options and warrants at the
grant dates in 2003, 2002 and 2001, consistent with the provisions of SFAS 123,
Med-Design's net loss and net loss per share would have reflected the proforma
amounts indicated below.
For the Years Ended December 31,
----------------------------------------------------------
2003 2002 2001
---- ---- ----
Net loss - as reported................................ ($ 6,046,489) ($ 8,081,061) ($ 4,026,991)
Total stock-based employee compensation expense
included in reported net loss.................... 1,483,286 1,783,863 1,792,082
Total stock-based employee compensation expense
determined under fair-value based method for all
awards........................................... (4,317,862) (6,794,591) (2,869,398)
------------- ------------- -------------
Pro forma net loss.................................... ($8,881,065) ($13,091,789) ($ 5,104,307)
------------- ------------- -------------
Net loss per share:
Basic and diluted loss per share - as reported........ ($0.42) ($0.67) ($0.38)
Basic and diluted loss per share - pro forma.......... ($0.62) ($1.08) ($0.48)
The fair value of each option or warrant grant was estimated using the
Black-Scholes option-pricing model with the following weighted-average
assumptions used for grants during the years ended December 31, 2003, 2002 and
2001: dividend yield of 0.00%; expected volatility of 97.76% to 100.97% and
range of risk free interest rate of 1.00% to 2.00% in 2003: dividend yield of
0.00%; expected volatility of 98.15% to 109.22% and range of risk free interest
rate of 2.00% to 3.00% in 2002: dividend yield of 0.00%; expected volatility of
90.66% and risk free interest rate of 4.32% to 5.11% in 2001. Expected lives are
based on actual terms of options and warrants granted.
F-9
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
2. Significant Accounting Policies, continued
Estimates Utilized in the Preparation of Financial Statements:
- --------------------------------------------------------------
The preparation of financial statements in conformity with generally
accepted accounting principles in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent liabilities at the date of
the financial statements and the reported amounts of expenses during the
reporting period. Actual results could differ from those estimates.
Comprehensive Income (Loss):
- ----------------------------
Comprehensive income (loss) consists of net income and other gains and
losses affecting shareholders' equity that, under generally accepted accounting
principles in the United States of America, are excluded from net income (loss).
Such items consist primarily of unrealized gains and losses on marketable equity
investments.
New Accounting Standards:
- --------------------------
In July 2003, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 150, "Accounting for
Certain Financial Instruments with Characteristics of Both Liabilities and
Equity". This Statement establishes standards for how to classify and measure
certain financial instruments with characteristics of both liabilities and
equity. It requires the classification of a financial instrument that is within
its scope as a liability. This Statement is effective for instruments entered
into or modified after May 31, 2003. The adoption of this pronouncement did not
affect the Company's financial position or results of operations.
In January 2003, the FASB issued Interpretation No. 46 or FIN 46,
"Consolidation of Variable Interest Entities", an interpretation of Accounting
Research Bulletin No. 51, "Consolidated Financial Statements". FIN 46
establishes accounting guidance for consolidation of variable interest entities
that function to support the activities of the primary beneficiary. In October
2003, the FASB issued FASB Staff Position FIN 46-6, "Effective Date of FASB
Interpretation No. 46, Consolidation of Variable Interest Entities" deferring
the effective date for applying the provisions of FIN 46 for public entities'
interests in variable interest entities or potential variable interest entities
created before February 1, 2003 until financial statements of interim or annual
periods that end after December 15, 2003. In December 2003, the FASB issued FIN
46 (revised December 2003), "Consolidation of Variable Interest Entities." This
revised interpretation is effective for all entities no later than the end of
the first reporting period that ends after March 15, 2004. The Company has no
investment in or contractual relationship or other business relationship with a
variable interest entity and therefore the adoption of this interpretation will
not have any impact on its consolidated financial position or results of
operations. However, if the Company enters into any such arrangement with a
variable interest entity in the future or an entity with which we have a
relationship is reconsidered based on guidance in the revised interpretation to
be a variable interest entity, the Company's consolidated financial position or
results of operations might be impacted.
F-10
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
3. Available-for-Sale Securities
Gross unrealized gains and losses for the years ended December 31, 2003, 2002
and 2001 are as follows:
Gross Gross
Unrealized Unrealized Estimated Fair
Amortized Cost Gains Losses Value
2003
U S government and agency securities $17,455,913 ($107,308) $17,348,605
Corporate debt securities 2,528,993 (48,422) 2,480,571
Publicly-traded corporate equity securities 1,119 617 1,736
---------------------------------------------------------------
Total $19,986,025 $617 ($155,730) $19,830,912
===============================================================
2002
U S government and agency securities $5,564,313 $92,837 $5,657,150
Corporate debt securities 4,505,445 96,073 4,601,518
Publicly-traded corporate equity securities 2,115,682 (126,180) 1,989,502
---------------------------------------------------------------
Total $12,185,440 $188,910 ($126,180) $12,248,170
===============================================================
2001
Corporate debt securities $4,432,742 $4,432,742
Other short term securities 31,879 31,879
Publicly-traded corporate equity securities 970,597 56,783 1,027,380
---------------------------------------------------------------
Total $5,435,218 $56,783 -- $5,492,001
===============================================================
Investment income for the years ended December 31, 2003, 2002 and 2001
was $693,765, $349,204 and $229,364 respectively.
During 2001, the Company sold 2,000 shares of Enpath Medical Inc.
common stock, which were received as part of a development and licensing
agreement in 2001, at a gain of $2,600. At December 31, 2001, Med-Design held
66,027 shares of Enpath Medical Inc. stock valued at $1,027,380 and included in
available-for-sale securities at December 31, 2001. At December 31, 2002, Med
- -Design held 235,442 shares of Enpath Medical Inc. common stock valued at
$1,989,502 and included in available-for-sale securities at December 31, 2002.
In accordance with FAS No. 115, "Accounting for Certain Investments in
Debt and Equity Securities", and consistent with the Company's accounting policy
for marketable equity securities, in the fourth quarter of fiscal 2002, the
Company determined that the decline in the fair value of its investment in
Enpath Medical Inc. stocks (which were received as part of development and
licensing agreement in 2001) was other than temporary. Accordingly, the Company
established a new basis of $448,078 in the investment, equivalent to its fair
market value at December 31, 2002. As a result, the Company realized a loss of
$331,419.
During 2003, Med-Design liquidated all but 132 shares of its remaining
holdings in Enpath Medical Inc. common stock at a gain of $108,821.
F-11
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
4. Property, Plant and Equipment
Balances of major classes of assets and accumulated depreciation and
amortization at December 31, 2003 and 2002 are as follows:
Estimated
Useful Lives
in Years 2003 2002
------------ ------------- -------------
Leasehold improvements................................... 3 $ 199,921 $ 199,921
Machinery and equipment.................................. 5-7 1,496,940 863,141
Office furniture & fixtures.............................. 7 312,201 329,516
Computer equipment & software............................ 2-5 140,115 111,155
------------- -------------
2,149,177 1,503,733
Less: Accumulated depreciation and amortization......... 1,366,305 1,158,603
------------- -------------
$ 782,872 $ 345,130
============= =============
Depreciation and amortization expense was $236,274, $338,771, and
$158,935 for the years ended December 31, 2003, 2002 and 2001, respectively.
5. Short-Term Borrowings
At December 31, 2003, Med-Design had a $3,000,000 revolving line of
credit under which borrowings would be collateralized by substantially all the
assets of the Company. This facility can be used to fund working capital needs
and finance capital equipment purchases; however, advances for capital equipment
financing may not exceed $600,000. Any borrowing to meet working capital needs
will bear interest at LIBOR plus 2.25%, while borrowings to finance capital
equipment purchases will bear interest at the prime rate plus 2.5%. There were
no borrowings under this facility during 2003 and 2002. The facility expires on
May 31, 2004.
6. Capital Lease Obligations
Capital lease obligations consisted of the following at December 31, 2003 and
2002:
2003 2002
------ ------
Capital lease obligations, at interest rates ranging from 8.3% to 12.66%,
with monthly payments ranging from $243 to $987; due through 2004........ $1,506 $4,080
Less: current maturities................................................... 1,506 2,574
------ ------
$ 0 $1,506
====== ======
F-12
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
7. Commitments and Contingencies
Med-Design leases a building, office space, and other office equipment
under non-cancelable operating leases that expire at various times through 2006.
Total rent expense under all operating leases for years ended December
31, 2003, 2002 and 2001 was $182,131, $164,422 and $160,975, respectively.
The aggregate amount of minimum future lease payments at December 31,
2003, which have remaining non-cancelable lease terms in excess of one year is a
follows:
2004................................ $185,104
2005................................ 190,657
2006................................ 162,429
2007................................ 199,788
2008................................ 173,231
--------
$911,209
========
In August, 2000, the Company's stockholders approved an employment
contract for the Company's Chairman and CEO, which provided for the issuance of
59,702 shares of common stock per year for an aggregate of 238,806, shares
beginning April 1, 2000, provided he remains an officer, director or consultant
of the Company. The fair value of Med-Design common stock at the date of
stockholder approval of this issuance of common shares was $12.63 per share. At
December 31, 2003, 59,702 shares remained unissued.
In August, 2000, Med-Design's shareholders approved the issuance of a
warrant to purchase 50,000 shares of common stock at an exercise price of $6.26
per share and the issuance of 125,000 shares of common stock to John F. Kelley,
a former director of the Company in connection with the performance of
consulting services. This compensation arrangement was approved, subject to the
conclusion of negotiations of Mr. Kelley's consulting contract. Negotiations
have not yet concluded.
The Company maintains employment agreements with its officers. The
agreements range from a period of two to five years. Although there are
conditions under which these agreements can be terminated before expiration, the
Company, at December 31, 2003, has a future compensation commitment of
$1,285,830 with respect to employment agreements.
8. Licensing Revenues
Becton Dickinson is the principal licensee of Med-Design's patented
product technology. Under the December 11, 1998 license agreement, Becton
Dickinson licensed certain of Med-Design's product technology and obtained an
option to license additional product technology.
On March 12, 2000, Med-Design signed a binding term letter with Becton
Dickinson outlining the terms for a definitive agreement pursuant to which
Becton Dickinson would license the products subject to the option to license.
Med-Design recorded as revenue $1.5 million in the form of an up-front licensing
fee upon the signing of the binding term letter. On May 11, 2000, Med-Design
entered into a definitive license agreement with Becton Dickinson based upon the
terms of the March 12, 2000 binding term letter pursuant to which Med-Design
received, and recorded as revenue, an additional $2.5 million in up-front
licensing fees and the right to receive royalty payments based on Becton
Dickinson's net sales of the products licensed under such agreement.
F-13
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
8. Licensing Revenues, continued
Enpath Medical Inc., formerly Medamicus, Inc., is also a licensee of
Med-Design's patented products. On September 25, 2000, Med-Design entered into a
development and licensing agreement granting Enpath Medical Inc. a license to
market and manufacture the Company's Safety Seldinger Introducer Needle for
certain venous applications. Under the terms of the agreement, Med-Design
receives royalty payments based on the net sales of the Safety Seldinger
Introducer Needle by Enpath Medical Inc.
On September 7, 2001, Med-Design entered into an Addendum ("the
Addendum") to the development and licensing agreement with Enpath Medical Inc.
The Addendum grants Enpath Medical Inc. an exclusive license to manufacture and
market the Company's Safety Seldinger Introducer Needle in the arterial access
market. Under the terms of the Addendum, Med-Design received an initial payment
of $2,000,000, $1,000,000 of which was paid in 68,027 shares of Enpath Medical
Inc. common stock valued at the closing price on the date the Company entered
into the Addendum and $1,000,000 of which was paid in cash on October 15, 2001.
In addition, Med-Design is entitled to receive royalties of 20% of net sales of
the product, which royalty rate may be reduced to 17% if certain sales volumes
are met.
9. Basic and Diluted Earnings Per Share
The following table sets forth the computation of basic and diluted loss per
share (EPS):
Weighted average
Loss shares outstanding EPS
----------- ------------------ -------
2003
Basic and diluted EPS
Net loss applicable to common stockholders ($6,046,489) 14,282,613 ($0.42)
----------- ---------- ------
2002
Basic and diluted EPS
Net loss applicable to common stockholders ($8,081,061) 12,116,143 ($0.67)
----------- ---------- ------
2001
Basic and diluted EPS
Net loss applicable to common stockholders ($4,026,991) 10,666,754 ($0.38)
----------- ---------- ------
Options and warrants to purchase 3,745,827, 2,611,619, and 2,096,413
shares of Med-Design's common stock as of December 31, 2003, 2002 and 2001,
respectively were not included in computing diluted earnings per share as the
effect of these instruments is anti-dilutive.
10. Stockholders' Equity
Common Stock
On March 25, 2002, Med-Design completed a private equity placement of
the Company's common stock. Med-Design sold 1,326,260 shares of its common stock
at a price per share of $11.31, or an aggregate of $15,000,000. The net proceeds
to the Company after the issuance costs were approximately $14,200,000.
On August 1, 2003, the Company completed a private equity placement of
its common stock in which the Company sold an aggregate of 3,598,844 shares of
its common stock at a price per share of $4.64, or an aggregate of
F-14
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
10. Stockholders' Equity, continued
$16,698,636. In addition, the Company sold to each purchaser in the private
equity placement warrants to purchase an aggregate of 1,199,607 shares of its
common stock at a price per share of $0.125. The exercise price of the warrant
is $6.03 per share. The net proceeds to the Company after giving effect to
issuance costs were approximately $16,000,000.
In connection with the private equity placement, Med-Design granted the
placement agent a five-year warrant to purchase 233,925 shares of Med-Design
common stock at an exercise price of $6.03 per share. The fair value of this
warrant was calculated using the Black-Scholes valuation model in accordance
with SFAS 123, is $1,055,844 and was recorded as issuance costs.
11. Stock Option Plans
In 1995, Med-Design adopted a Non-Qualified Stock Option Plan ("Stock
Option Plan"), which provides for the grant of 1,000,000 (as adjusted to reflect
a 2 for 1 stock split effective February 12, 1996) options to directors,
officers and employees of the Company. Under the Stock Option Plan, the exercise
price of each option may not be less than the fair market value (as of the date
of grant) of the Company's common stock and the term of each option may be no
more than 10 years from the date of grant. Additionally, the Stock Option Plan
provides for the annual issuance of options for the purchase of 10,000 shares of
common stock to each non-employee director.
Options granted to employees under the Non-Qualified Option Plan vest
at a rate of 20% or 33 1/3% per year and expire either, in five, seven or ten
years from the date of grant. Certain option grants include accelerated vesting
provisions based upon achieving stock trading values or earnings per share.
Options granted to Directors expire at the end of five years and vest one year
from the date of grant.
On June 11, 2001, the Board adopted the 2001 Equity Compensation Plan,
the "2001 Plan". The 2001 Plan provides for the grant of 1,690,000 shares to
directors, officers and employees of the Company and is administered by the
Company's Compensation Committee. The Compensation Committee has the authority
to (i) determine the individuals to whom grants will be made under the 2001
Plan; (ii) determine the type, size and terms of each grant; (iii) determine the
time when grants will be made and the duration of any applicable exercise or
restriction period; (iv) amend the terms of any previously issued grant; and (v)
deal with any other matters arising under the Plan.
As of December 31, 2003 there were 144,073 shares available for future
grants which may be applied to either plan.
On October 10, 2002, Med-Design issued a stock option to purchase
29,297 shares of common stock to a consultant at an exercise price of $3.25 per
share. The stock option vests as to 14,648 shares per year on each of the first
two anniversaries of the date of the grant, and expire on October 10, 2007 and
2009. The stock option remained unexercised at December 31, 2002.
On September 22, 2003, Med-Design issued a stock option to purchase
25,000 shares of common stock to a consultant at an exercise price of $4.52 per
share. The option vests as to one half of the underlying shares per year on each
of the first two anniversary dates and expire on September 22, 2013.
On September 22, 2003, Med-Design issued a stock option to purchase
25,000 shares of common stock to a director of the Company at an exercise price
of $4.52 per share for consulting services. The stock option vests on September
22, 2009 and expires on September 22, 2013. Vesting is accelerated upon the
completion of certain specific events related to the financial performance of
the Company. The stock option remained unexercised at December 31, 2003.
On September 22, 2003, Med-Design issued a stock option to purchase
5,000 shares of common stock to a consultant of the Company for consulting
services at an exercise price of $4.52 per share. The stock option vested on
September 22, 2003 and expires on September 22, 2013. The stock option remained
unexercised at December 31, 2003.
F-15
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
11. Stock Option Plans, continued
Activity under the stock option plans during the years ended December
31, 2003, 2002 and 2001 is as follows:
2003 2002 2001
---------------------------- ---------------------------- -----------------------------
Weighted Weighted Weighted
Average Average Average
Exercise Exercise Exercise
Options Shares Price Shares Price Shares Price
- --------------------------- --------------- --------- --------------- --------- --------------- ---------
Granted.................... 327,794 4.69 817,296 6.68 656,773 14.86
Exercised.................. (20,900) 1.53 (37,400) 2.19 (192,700) 5.16
Forfeited.................. (146,850) 13.64 (54,320) 16.71 (56,000) 3.25
Expired.................... -- -- -- -- (16,000) 3.25
--------------- --------- --------------- --------- --------------- ---------
Outstanding at end of
year.................... 1,985,593 $ 8.99 1,825,549 $ 9.97 1,099,973 $12.54
=============== ========= =============== ========= =============== =========
Options exercisable at
year-end................ 1,219,114 912,088 350,100
=============== =============== ===============
Option price range at end
of year.................... $1.56 to $17.97 $0.81 to $17.97 $0.81 to $17.97
=============== =============== ===============
Weighted-average fair value
of options granted during
year....................... $4.12 $5.66 $10.75
=============== =============== ===============
The following table summarizes information regarding stock options outstanding
at December 31, 2003:
Options Outstanding Options Exercisable
--------------------------------------------------------- ----------------------------------
Number
Outstanding at Weighted-Average Weighted-Average Number Weighted-Average
Range of December 31, Remaining Exercise Outstanding at Exercise
Exercise Prices 2003 Contractual Life Price December 31, 2003 Price
- --------------------- ----------------- ------------------ -------------- ------------------ -------------
$1.56 to $3.35 511,500 6.9 $ 3.14 212,500 $ 2.96
$4.14 to $8.48 538,338 7.4 $ 6.26 277,610 $ 6.54
$11.01 to $17.97 935,755 3.7 $ 13.74 729,004 $13.90
---------- ------------- ------- --------- ------
1,985,593 5.5 $ 8.99 1,219,114 $10.32
========== ============= ======= ========= ======
F-16
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
12. Stock Based Compensation
The Company entered into arrangements, subject to shareholder approval,
which was obtained on August 7, 2000, for the issuance of shares of common
stock, stock options and warrants to purchase shares of common stock to officers
of the Company during 2000. Compensation expense in the amount of $1,483,286,
$1,783,863 and $1,792,082 was recorded during the years ended December 31, 2003,
2002 and 2001 based on the difference between the exercise price of the options
and warrants and the fair value of Med-Design's common stock on August 7, 2000
of $12.63 and calculated in accordance with the individual vesting schedules of
these grants.
In August, 2000, the Company's stockholders approved an employment
contract for the Company's Chairman and CEO, which provided for the issuance of
59,702 shares of common stock per year for the next four years totaling 238,806
shares beginning April 1, 2000 provided he remains an officer, director or
consultant of the Company. The fair value of Med-Design common stock at the date
of shareholder approval of this grant was $12.63 per share. Compensation expense
of $822,228 was recorded in 2003 and 2002.
In November 1999, the Company approved the issuance, subject to
shareholder approval, which was received in August 2000, of 200,000 shares of
common stock to the Chief Operating Officer. The stock vests at the earlier of
the date when the Company's common stock trades at $22.00 or higher for 30 days
or November 11, 2004 provided he has not resigned or been discharged for cause.
On July 6, 2001, Med-Design stock maintained a market price of $22.00 or higher
for 30 days and this agreement was revised to provide that a third of the stock
vests on August 6, 2001 and the remaining shares vested in two equal tranches on
August 6, 2002 and August 6, 2003. In connection with the August 6, 2001
issuance, the Company recorded compensation expense of $944,812 during the year
ended December 31, 2001, (based on the fair value of Med-Design's common stock
on August 7, 2000 of $12.63 per share). Compensation expense of $841,668 and
$490,974 was recorded in 2002 and 2003.
On March 15, 2002, the Company issued warrants to purchase 18,000
shares of common stock at an exercise price of $12.50 per share to each of two
consultants for consulting services rendered through March 15, 2005 and recorded
compensation expense of $100,483 and $79,549 during the years ended December 31,
2003 and 2002, respectively, based on the fair value of the warrants, calculated
using the Black-Scholes valuation model.
On October 10, 2002, the Company issued a stock option to purchase
29,297 shares at an exercise price of $3.25 per share for consulting services to
be rendered through October 10, 2003 and recorded compensation expense of
$33,084 and $17,151 during the years ended December 31, 2003 and 2002, based on
the fair value of the warrant, calculated using the Black-Scholes valuation
model.
On September 22, 2003, the Company issued a stock option to purchase
25,000 shares of common stock at an exercise price of $4.52 per share to a
consultant for consulting services to be rendered through September 22, 2005 and
recorded compensation expense during the year ended December 31, 2003 in the
amount of $12,654 based on the fair value of the stock options, calculated using
the Black-Scholes valuation model.
On September 22, 2003, the Company issued a stock option to purchase
25,000 shares of common stock at an exercise price of $4.52 per share to a
director for consulting services and recorded compensation expense during the
year ended December 31, 2003 in the amount of $3,656 based on the fair value of
the stock options, calculated using the Black-Scholes valuation model.
On September 22, 2003, Med-Design issued a stock option to purchase
5,000 shares of common stock at an exercise price of $4.52 per share to a
consultant for consulting services and recorded compensation expense during the
year ended December 31, 2003 in the amount of $20,247 based on the fair value of
the stock options calculated using the Black-Scholes valuation model.
F-17
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
13. Warrants Outstanding
As of December 31, 2003 and 2002, warrants to purchase a total of
1,700,532 and 600,000 shares of Med-Design's common stock were outstanding with
various vesting and expiration periods as outlined below.
On January 14, 1998, Med-Design issued a warrant to purchase 100,000
shares of common stock at an exercise price of $2.88 per share to a director of
the Company who was engaged to perform consulting services. The warrant was
exercisable upon issuance and was exercised on January 14, 2003.
On September 9, 1998, Med-Design issued a warrant to purchase 200,000
shares of common stock at a price of $1.25 per share to a director of the
Company who was engaged to perform consulting services. This warrant vested upon
completion of performance on December 23, 1998 and was exercised in August 2003.
On January 21, 1999, Med-Design issued a warrant to purchase 50,000
shares of common stock at an exercise price of $3.25 to a director of the
Company who was engaged to perform consulting services. The warrant was
exercisable upon issuance and was exercised on January 21, 2004.
On March 5, 1999 Med-Design issued a warrant to purchase 100,000 shares
of common stock at $3.94 per share to an officer of the Company. The warrant
vested on March 5, 2000 and expires on March 5, 2004. The warrant was exercised
as to 25,000 shares on November 2, 2000. The warrant remained unexercised as to
75,000 shares at December 31, 2003.
On November 5, 1999, in connection with the acquisition of a patent,
Med-Design issued a warrant to purchase 25,000 shares of common stock at an
exercise price of $8.00 per share. The warrant is exercisable on or before
November 5, 2004. The warrant was exercised as to 15,000 shares on July 27,
2001. The warrant remained unexercised as to 10,000 shares at December 31, 2003.
On February 18, 2000, the Company issued a warrant to purchase 40,000
shares of common stock to a director of Med-Design in connection with his
separation from the Company. The warrant vested upon issuance, expires on
February 18, 2005 and has an exercise price of $16.375. The warrant remained
unexercised at December 31, 2003.
On April 25, 2000, Med-Design issued a warrant to purchase 66,000
shares of common stock at $11.875 per share to its Chief Operating Officer. The
warrant vested as to 33,000 shares in November 2000 and 33,000 shares in
November 2001 and expires April 25, 2005. The warrant was cancelled in December
2003 due to the resignation of the officer.
On April 25, 2000, Med-Design issued a warrant to purchase 66,000
shares of common stock at $11.875 per share to its Chief Financial Officer. The
warrant vested as to 33,000 shares on November 2000 and 33,000 shares in
November 2001 and expires on April 25, 2005. The warrant was exercised as to
50,000 shares on July 10, 2001. The warrant remained unexercised as to 16,000
shares at December 31, 2003.
On March 15, 2002, Med-Design issued two warrants to purchase 18,000
shares of common stock at $12.50 per share to each of two consultants. The
warrants vest one-third a year on each anniversary date for the next three years
and expire on December 27, 2007. The warrants remained unexercised at December
31, 2003.
On March 22, 2002, Med-Design issued a warrant to purchase 40,000
shares of common stock at $14.1375 per share to an agent in connection with its
services as a placement agent in a private equity placement. The warrant vested
immediately and expires on March 22, 2007. The warrant had a fair value of
$319,604, calculated using the Black Scholes model, which was included in
private equity issuance costs. The warrant remained unexercised at December 31,
2003.
F-18
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
13. Warrants Outstanding, continued
On August 1, 2003, in connection with a private equity placement,
Med-Design issued warrants to purchase 1,199,607 shares of common stock to
investors in the private placement. The warrants vested upon issuance and expire
on August 1, 2008. The exercise price of the warrants is $6.03. The warrants
remain unexercised at December 31, 2003.
On August 1, 2003, in connection with the private equity placement,
Med-Design issued warrants to purchase 233,925 shares of common stock to the
placement agent. The warrants have an exercise price of $6.03 and vested upon
issuance. The warrants expire on August 1, 2008. The warrants had a fair value
of $1,055,821, calculated using the Black Scholes model, which was recorded as
issuance costs. The warrants remained unexercised at December 31, 2003.
14. Defined Contribution Benefit Plan
Med-Design sponsors a 401(k) defined contribution benefit plan.
Participation in the plan is available to substantially all employees. The
Company makes an annual contribution of 3% of gross salaries for all eligible
employees. The Company made its first contribution to the plan in 2003 of
$52,410. No amounts were contributed in 2002 and 2001.
15. Income Taxes
The following is a summary of the components of income taxes from
operations:
2003 2002 2001
------------- ------------- -------------
Current Provision
Federal.................................... $ -- $ -- $ --
State...................................... -- -- --
------------- ------------- -------------
-- -- --
Deferred tax provision (benefit)
Federal.................................... (2,501,691) ( 3,448,520) (2,320,636)
State...................................... (277,372) ( 1,329,290) (334,607)
------------- ------------- -------------
Total provision (benefit) for income taxes. (2,729,063) ( 4,777,810) (2,655,243)
Less: Valuation allowance.................. 2,729,063 4,777,810 2,655,243
------------- ------------- -------------
$ -- $ -- $ --
============= ============= =============
F-19
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
15. Income Taxes, continued
The deferred income tax assets and liabilities recorded in the
consolidated balance sheets at December 31, 2003, 2002 and 2001 are as follows:
2003 2002 2001
------------ ------------ -------------
Assets
Loss carryforwards.......................... 15,778,858 12,411,976 8,256,135
Research and development tax credit......... 492,317 474,049 457,593
Amortization................................ 1,119,965 641,813 866,213
Deferred compensation expense............... 667,939 1,276,106 572,716
Other....................................... (431,941) 94,131 (32,393)
------------ ------------ -------------
Total deferred tax assets................... 17,627,138 14,898,075 10,120,264
Valuation allowance......................... (17,627,138) (14,898,075) (10,120,264)
------------ ------------ -------------
Net deferred tax assets (liabilities)....... $ -- $ -- $ --
============ ============ =============
At December 31, 2003, the Company has a federal net operating loss
carry forward of approximately $51 million which will expire in the years 2010
through 2022. At December 31, 2003, the Company has a net operating loss for
state purposes of approximately $47 million which will expire in the years 2004
through 2012.
Included in the net operating loss carryforward is certain option and
warrant exercises that total approximately $14.0 million at December 31, 2003.
However, these benefits were deferred because the Company is in a net operating
loss position. Such benefits will be credited to additional paid-in capital in
the year in which the benefits are realized.
In addition, the Company experienced an ownership change in accordance
with Internal Revenue Code Section 382 in 1997. Losses incurred through January
23, 1997 amounting to $4.9 million are generally limited in their utilization to
$1.7 million per year. It is possible that recent ownership changes may result
in further limitations under Section 382
The Company has unused research tax credit in the amount of $.5 million
which will expire in the years 2010 through 2022.
A reconciliation of the Federal statutory rate (34%) to the effective
tax rate is as follows:
2003 2002 2001
----------- ------------- -----------
Tax at U.S. statutory income tax rate...... (2,046,884) ( 2,705,872) (1,409,447)
True-up of net operating losses - relating -- ( 742,648) (844,977)
to stock based compensation.............
Other...................................... (454,808) -- (66,212)
Increase in Valuation Allowance............ 2,501,692 3,448,520 2,320,636
----------- ------------- -----------
$ -- $ -- $ --
=========== ============= ===========
F-20
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
16. Related Party Transactions
During 2003, 2002 and 2001, the Company paid $22,717, $26,610 and
$44,265 respectively, for legal services to a firm, of which a partner is a
director, officer and stockholder of Med-Design.
On April 15, 2002, pursuant to a Note and Pledge Agreement, the Company
loaned $250,000 to Michael W. Simpson, the Company's former Chief Operating
Officer, which was collateralized by 66,666 shares of Med-Design's common stock
issued to Mr. Simpson on August 6, 2003. The Note was repayable on the earlier
of (i) April 15, 2004, (ii) the date on which Mr. Simpson ceased to be an
employee, consultant or director of Med-Design, (iii) the date on which
Med-Design provided notice to Mr. Simpson that the closing price of the common
stock had been $30.00 or higher for 20 consecutive days as reported on the
Nasdaq National Market, or (iv) the date on which Mr. Simpson sold or
transferred the pledged securities. The Note accrued interest at 16% per year
until the issuance of the pledged securities to Mr. Simpson on August 6, 2003,
as of which time the Note accrued interest at the prime lending rate plus 1%.
On April 25, 2003, the Company entered into a new employment agreement
with Mr. Simpson following his resignation as director and officer of the
Company as of March 13, 2003. The initial term of the agreement was from March
20, 2003 through July 15, 2003. Under the agreement, Mr. Simpson was to receive
total compensation of $45,538 for the initial period of the agreement. Total
compensation for the initial period was increased on June 10, 2003 by $14,230
for a total of $60,480. In addition, the new employment agreement provided for
the deferral, until its termination, of the $46,250 in severance that Mr.
Simpson was entitled to under his previous employment agreement. On July 14,
2003, the Company extended the agreement with Mr. Simpson to August 15, 2003.
Following termination of the agreement on August 15, 2003, the Company began
making payments to Mr. Simpson of the severance amounts (which payments were
required to be made in equal monthly installments through December 15, 2003).
On October 23, 2003, the Company entered into an agreement with Mr.
Simpson regarding the repayment of the $250,000 Note issued on April 15, 2002
and all accrued interest thereunder. Under the terms of this agreement, the
Company cancelled the Note issued on April 15, 2002 (the "Old Note") and issued
a new note (the "New Note") to Mr. Simpson evidencing the $250,000 outstanding
principal amount. The New Note was effective as of November 15, 2003, matures on
November 15, 2006 and accrues interest at 5% per year. The New Note requires
monthly payments to the Company of $1,500 until maturity, with the remainder of
the then outstanding principal and interest due November 15, 2006, and is
collateralized by a mortgage on real property owned by Mr. Simpson. Pursuant to
the terms of the agreement, the Company released to Mr. Simpson a stock
certificate evidencing the 66,666 shares of Med-Design common stock and Mr.
Simpson was obligated to pay the Company the accrued interest of $28,925 on the
Old Note within 15 working days of his receipt of a signed copy of the
agreement, a stock certificate evidencing the 66,666 shares of Med-Design common
stock, a legal opinion on the transferability of such shares and a prospectus
pursuant to which the shares may be sold.
The Company recently filed a registration statement covering the resale
of the shares of its common stock by a number of its security holders. Such
registration statement includes the 66,666 shares of Med-Design common stock
held by Mr. Simpson.
The agreement also provides for the payment in full of the New Note
upon the sale of the real property collateralizing the New Note. In addition, if
Mr. Simpson sells any of his 66,666 shares of Med-Design common stock, a
percentage of the proceeds of such sale, such percentage to be agreed upon at
the time of the sale by the parties, will be paid to the Company to reduce the
balance on the New Note. Under the agreement, the Company also agreed to
consider in its sole discretion paying Mr. Simpson a cash bonus, in such amount
that the Company may determine in its sole discretion, for any Company project
in which Mr. Simpson was engaged during his employment with the Company if such
project results in a revenue-producing event for the Company, provided that such
event occurs by August 15, 2004.
F-21
THE MED-DESIGN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, CONTINUED
16. Related Party Transactions (continued)
On February 26, 2004, Mr. Simpson advised the Company that he is unable
to fulfill his obligations under the New Note. The Company therefore recorded a
charge at December 31, 2003 of $250,000 plus accrued interest of $28,925 as a
bad debt expense. The Company is evaluating alternative measures to enforce
payment under the New Note by virtue of a prior lien.
17. Fair Value of Financial Instruments
The following methods and assumptions were considered by Med-Design in
determining its fair value disclosures for financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance
sheet approximates fair value.
Marketable securities: Available-for-sale securities consist of corporate bonds,
common stock and commercial paper. Fair value is based on quoted market prices.
18. Quarterly Information (unaudited)
Quarter Ended
-----------------------------------------------------------------------
2003 March 31 June 30 September 30 December 31
- ---- ---------------- ---------------- --------------- ---------------
Revenue....................................... $ 39,091 $ 42,145 $ 140,135 $ 605,354
Operating loss................................ ($ 1,909,624) ($ 1,763,085) ($ 1,710,535) ($ 1,386,690)
Net income (loss)............................. ($ 1,756,269) ($ 1,590,436) ($ 1,472,680) ($ 1,227,104)
Basic and diluted earnings (loss) per share... ($0.14) ($0.13) ($0.10) ($0.05)
Quarter Ended
-----------------------------------------------------------------------
2002 March 31 June 30 September 30 December 31
---------------- ---------------- --------------- ---------------
- ----
Revenue........................................ $ 6,695 $ 7,019 $ 9,089 $ 451,522
Operating income (loss)........................ ($ 1,702,046) ($ 2,337,752) ($ 1,945,486) ($ 2,112,520)
Net income (loss).............................. ($ 1,676,760) ($ 2,274,949) ($ 1,873,745) ($ 2,255,607)
Basic and diluted earnings (loss) per share.... ($0.15) ($0.18) ($0.15) ($0.18)
F-22